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ABSTRACT
The first chapter discusses the significance of natural products, safety challenges, and
quality issues concisely. Specifically, the impact of herb-drug interaction on consumers and the
quest for chemical markers for chemical fingerprinting development are provided.
Rooibos tea (Aspalathus linearis) is a popular South African herbal tea enjoyed
worldwide. Limited reports indicate the potential of rooibos tea to alter the activity of CYP450
isozymes. In chapter two, the phytochemical investigation of A. linearis resulted in the isolation
and characterization of 14 phenolic compounds. Safety assessment of the phytochemicals
through interaction with CYP, PXR, and P‑gp was conducted. The results indicate that a high
intake of nutraceuticals containing rooibos extracts may pose a risk of herb-drug interactions
when consumed with clinical drugs that are substrates of CYP enzymes.
In chapter three, a comprehensive quantitative analysis of phenolic compounds from
rooibos tea and dietary supplements using UHPLC-PDA-MS was developed to determine 14
chemical constituents. The compounds were detected in the range from 1.50- 9.85 % in twentyone dietary supplements with higher content observed for the unfermented products. The
characterization and confirmation of components were achieved by LC-ESI-MS. Selective ion
monitoring with the positive and negative ion modes was involved for this purpose.
Moringa oleifera Lam. is known as a miracle tree that cultivated in subtropical and
tropical provinces. In chapter four, phytochemical investigation of M. oleifera resulted in the
isolation and characterization of one new compound, namely omoringone, alongside fifteen
known secondary metabolites. Structure elucidation was achieved by interpretation of the
ii

spectroscopic data and confirmation by HR-ESI-MS. A plausible biosynthetic pathway for
omoringone was provided. Because of the low isolation yields and limited supply, omoringone
and niazirin were successively synthesized. All the isolates were evaluated for their potential
cytotoxicity and drug interaction potential.
In chapter five, profiling and quantification of key phytochemicals from M. oleifera and
herbal supplements by UHPLC-PDA-MS were implemented for the determination of nine
phytochemicals with an efficient separation performed within 7 min. The optimized method was
robust, economical and suitable for chemical fingerprint analysis of M. oleifera herbal
supplements.
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CHAPTER 1:

GENERAL INTRODUCTION AND OVERVIEW

1.1

The significance of natural products:

Natural sources such as plant, marine, microbial, animal or fungi comprise a plethora of diverse
bioactive components (Figure 1-1). Due to this diversity, natural product compounds are
exploited in the development of numerous therapeutic agents. The ancient civilizations of the
Chinese, Indians, Africans, and Amazonians provided written evidence for the use of natural
sources for therapeutic purposes. In the areas of cancer and infectious disease, 60 and 75%,
respectively, of new drugs, originate from natural sources. Moreover, 26% of FDA approved
drugs from 1981 until 2014 are naturally derived compounds (Figure 1-2).(Newman & Cragg,
2016) On the other hand, people have often perceived herbs as not only natural but also safe.
According to previous studies, 80% of public rely primarily on traditional remedies for their
treatments, and 48% of cancer patients are potentially taking herbal medicines.(Ekor, 2014)
Myriad factors have contributed to public interest in natural products such as established
traditional use, easy availability, and reasonable value.
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Figure 1-1: Natural product compounds are derived from several sources
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Figure 1-2: All new approved drugs 1981−2014; n = 1562. Among them, 26% are naturally
derived compounds.(Newman & Cragg, 2016)

3

1.2

Safety challenges:

The growing intake of herbal medicines led to issues relating to adverse reactions and difficulties
in monitoring safety. The fact that the majority of patients do not report their herbal consumption
to their physician aggravated the safety issue of herbal products. Myriad side effects were
reported to the FDA's Adverse Event Reporting System by healthcare providers owing to active
ingredients.(Ekor, 2014) A range of commonly used herbal products such as St. John’s wort,
ginseng, grapefruit juice, Echinacea, and licorice, interact with conventional medicines and exert
adverse events on the circulatory, endocrine, or nervous systems.(Tachjian et al., 2010)
Devastating effects on the quality of life for the consumers are probably underestimated because
of the lack of scientific evidence for the safety and efficacy of these products. Due to side effects
related to dietary supplements, the number of emergency department visits was estimated as
23,005 cases resulting in 2,154 hospitalizations annually.(Geller et al., 2015) Therefore, it is
crucial for scientists to protect the public health by ensuring the safety and quality of herbal
remedies.
Multiple endogenous substrates and exogenous xenobiotics are predominantly metabolized and
biosynthesized by Cytochrome P450. These heme-containing mono-oxygenases are exclusively
responsible for the conversion of the inactive prodrug to the pharmacologically active
metabolites in the human body. The principal CYP isoforms accounted for 80% of the clinical
drugs metabolism include CYP3A4, CYP2D6, CYP2C9, CYP1A2, and CYP2C19 (Figure 1-3).
Both CYP inducers and inhibitors interact with CYP isozymes and interfere with CYP substrates
in the binding site.(Denisov et al., 2005) While CYP inhibitors can intensify the toxicity profile
of other medicines being accumulated in the body, CYP inducers have the ability to eliminate the
drugs from the biological system rapidly resulting in diminished activity. Therefore,
4

determination of components potentially responsible for interaction with clinical drugs via CYP
enzymes is pivotal.

21%

30%

CYP3A4
CYP2D6

7%

CYP2C9
9%

CYP1A2
20%

13%

CYP2C19
Other

Figure 1-3: The major CYP isoforms accounted for 80% of the clinical drugs metabolism.

1.3

The quest for chemical markers and development of a fingerprint profile as a
valuable tool for quality assurance:

Herbal medicines often contain a principal and unique component which can be considered as a
chemical marker. If this abundant compound is non-specific and reported from several plant
species, an array of compounds should be employed in the analytical method to enhance the
selectivity properties and avoid misidentification. The versatile applications for the chemical
markers encompass authentication of plant material, differentiation of related-species, detection
of the adulterants, selection of efficient extraction methods, and discrimination of processed from
unprocessed samples.(Osman et al., 2019)
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1.4

Specific aims and the overall goal of the dissertation:

This dissertation is divided into four specific aims emphasizing the safety and quality of two
medicinal plants commonly consumed as herbal teas; Aspalathus linearis (rooibos tea) and
Moringa oleifera (miracle tree) as depicted (Scheme 1-1). Each aim is considered as a separated
chapter, and an abstract is provided, at the beginning of each chapter, in which describes the
content of the section concisely for the reader.

AIMS

METHODOLOGY

TIMELINE

CHAPTER 2

CHAPTER 3

CHAPTER 4

CHAPTER 5

SPECIFIC AIM 1
Safety assessment of
phytochemicals derived
from the globalized
South African rooibos
tea (Aspalathus
linearis) through
interaction with CYP,
PXR, and P-gp

SPECIFIC AIM 2
Chemical fingerprint
profile and
comprehensive
quantitative analysis
of phenolic
compounds from
South African rooibos
tea (A. linearis) and
dietary supplements
using UHPLC-PDAMS
1. Method
development
2. Method validation
3. Identification and
quantification 14
chemical markers in
21 herbal supplements
claimed to contain A.
linearis by UHPLCPDA-ESI-Q-MS

SPECIFIC AIM 3
Isolation, synthesis, and
drug interaction
potential of secondary
metabolites derived
from the miracle tree
(Moringa oleifera)
leaves against CYP3A4
and CYP2D6 isozymes

SPECIFIC AIM 4
Profiling and
quantification of
selected
phytochemicals from
the miracle tree (M.
oleifera) and dietary
supplements by
UHPLC-PDA-MS

1. Extraction and
isolation of compounds
using extensive
chromatographic
techniques
2. Structure elucidation,
characterization by 1D
and 2D NMR
expriments and
confirmation by HRESI-MS
3. Synthesis of two
compounds
3. Cytotoxicity assay
4. CYP3A4 and
CYP2D6 analysis

1. Method
development
2. Method validation
3. Identification and
quantification of 9
chemical markers in
13 herbal
supplements claimed
to contain M. oleifera
by UHPLC-PDAESI-Q-MS

1. Extraction and
isolation of compounds
using extensive
chromatographic
techniques
2. Structure elucidation,
characterization by 1D
and 2D NMR
expriments and
confirmation by HRESI-MS
3. Recombinant CYP
assay
4. PXR Modulation by
luciferase reporter gene
assay
5. P-glycoprotein
Inhibition assay
6. RT-PCR analysis of
CYP3A4, CYP1A2,
CYP2C9, and P-gp
mRNA

The 1st and 2nd years (2015-2016)

The 3rd and 4th years (2017-2018)

Scheme 1-1: Outline of specific aims for the research proposal
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2

CHAPTER 2:

SAFETY ASSESSMENT OF PHYTOCHEMICALS DERIVED FROM THE
GLOBALIZED SOUTH AFRICAN ROOIBOS TEA (ASPALATHUS LINEARIS)
THROUGH INTERACTION WITH CYP, PXR, AND P-GP
Abstract:
Rooibos tea (Aspalathus linearis) is a well-known South African herbal tea enjoyed worldwide.
Limited reports indicate the potential of rooibos tea to alter the activity of certain CYP450
isozymes. In this study, the phytochemical investigation of MeOH extract of A. linearis (leaves
and stems) resulted in the isolation and characterization of 12 phenolic compounds. The MeOH
extract exhibited significant inhibition of the major human CYP450 isozymes (CYP3A4,
CYP1A2, CYP2D6, CYP2C9, and CYP2C19). The strongest inhibition was observed by the
extract for CYP3A4 (IC50 1.7 ± 0.1 µg/mL) followed by CYP2C19 (IC50 4.0 ± 0.3 µg/mL).
Among the tested phytochemicals, the most potent inhibitors were isovitexin on CYP3A4 (IC 50
3.4 ± 0.2 µM), vitexin on CYP2C9 (IC50 8.0 ± 0.2 µM), and thermopsoside on CYP2C19 (IC50
9.5 ± 0.2 µM). The two major, structurally related compounds, aspalathin and nothofagin
exhibited a moderate PXR activation, which was associated with increased mRNA expression of
CYP3A4 and CYP1A2. These results indicate that a high intake of nutraceuticals containing
rooibos extracts may pose a risk of herb-drug interactions when consumed concomitantly with
clinical drugs that are substrates of CYP enzymes.
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2.1

Introduction:

The Aspalathus genus is classified as a member of the pea family, Leguminosae, and it
comprises more than 270 plant species. Interestingly, Aspalathus linearis (Burm.f.) R. Dahlgren,
commonly known as rooibos tea, is recognized to be the only edible Aspalathus species so far. It
is a perennial shrub endemic to the western parts of the Cape region in South Africa.(E. Joubert
& de Beer, 2011; Krafczyk & Glomb, 2008) It grows naturally in the Cederberg Mountains
encompassing the Citrusdal, Clanwilliam and Nieuwoudtville regions, which are considered the
commercial epicenters of the rooibos industry. The leaves and stems are used for the production
of the refreshing rooibos drink which contains no caffeine and only minimal levels of tannins. In
addition to anti-oxidant properties, it displays hypoglycemic, anti-allergic, antispasmodic,
photoprotective, anti-inflammatory, and estrogenic activities.(Baba et al., 2009; Gilani et al.,
2006; Johnson et al., 2018; Kawano et al., 2009; Lee & Bae, 2015; Magcwebeba et al., 2016;
Shimamura et al., 2006; Smith & Swart, 2016; Son et al., 2013)
Although rooibos is a popular herbal tea in more than 37 countries, it has recently attracted
greater global attention as a health beverage. The export price spiked dramatically between 2010
and 2014 because of the increased demand and reputation. Additionally, the Swiss Business Hub
South Africa report anticipated that ordinary tea (Camellia sinensis) followed by the rooibos tea
would become the two most abundant and widely distributed teas in the world.(E. Joubert & de
Beer, 2011) Oxidation and browning of green rooibos, that takes place during “fermentation”,
alters the phenolic profile and biological properties of the tea. Consequently, two types of
rooibos teas are available, unfermented (green) and fermented (red).(E. Joubert & de Beer, 2011;
Marais et al., 2000)
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Although two clinical reports indicated a hepatotoxic effect of rooibos tea extract in humans, it is
generally considered safe when ingested as a tisane.(Engels et al., 2013; Sinisalo et al., 2010)
Herbal supplements may cause unexpected toxicity by altering drug metabolizing enzymes such
as cytochrome P450 (CYP450) and drug transporters when administered in conjunction with
conventional pharmaceutical drugs.(Fasinu et al., 2017) Despite little evidence available to
describe the adverse effects, herbal supplements containing rooibos ingredients were found to
inhibit CYP2C11 isozyme expression.(Jang et al., 2004) When comparing the unfermented and
fermented rooibos extracts, researchers observed the inhibitory activity of both extracts on
CYP2C8, CYP2C9, and CYP3A4 isozymes.(Patel et al., 2016) Conversely, in an animal study, a
rooibos extract was also shown to induce the activity of intestinal and hepatic CYP3A isoforms
and upregulate the CYP3A contents.(Matsuda et al., 2007) Moreover, recently published studies
found that rooibos tea has modulated the steroid biosynthesis and influenced rat liver
enzymes.(Schloms et al., 2012; Schloms & Swart, 2014; van der Merwe et al., 2015)
Nevertheless, all studies on the biological properties, except one, lack key information on the
chemical compositions of the infusions or extracts used in the experiments. The study
highlighted the ability of aspalathin, a C-glucosyl dihydrochalcone derivative, to inhibit the
activity of CYP3A4 in a time-dependent assay compared with erythromycin.(Patel et al., 2016)
In our continued quest to explore the quality and safety of botanical ingredients, we aim to
investigate the herb-drug interaction (HDI) profile of the MeOH extract of unfermented rooibos
tea and the isolated secondary metabolite constituents on drug metabolizing enzymes and efflux
transporter (CYPs and P-gp). The rationale for selecting MeOH was due to its superiority as an
extraction solvent of the majority of secondary metabolites. In order to differentiate the integrity
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of secondary metabolism associated with A. linearis, unfermented material (dried leaves and
stem) was selected for isolation, characterization, and drug interaction potential studies.
2.2

Materials and methods:

2.2.1 Biochemicals and reagents:
Inhibitor screening kits for recombinant human CYPs including CYP3A4/BQ, CYP2D6/AMMC,
CYP1A2/CEC, CYP2C9/MFC, and CYP2C19/CEC along with substrates and buffer systems
were purchased from BD Gentest (Woburn, MA, USA). Both parental and transfected cell lines
(MDCK-II and hMDR1-MDCK-II) were obtained from Dr. Gottesman (NIH, Bethesda, MD,
USA). Transwell plates were purchased from Costar Corp. (Cambridge, MA, USA). All positive
controls (ketoconazole, quinidine, furafylline, sulfaphenazole, tranylcypromine, rifampicin, and
omeprazole) were purchased from Sigma Chem. Co., (St. Louis, MO, USA). Their stability was
monitored and purity was determined to be more than 95%. Troleandomycin, with purity higher
than 98%, was obtained from Santa Cruz Biotechnology, Inc. FBS was obtained from Hyclone
Lab Inc. (Logan, UT, USA). Hanks balanced salt solution (HBSS), minimal essential medium
(MEM), Dulbecco's modified eagle medium (DMEM), DMEM‑F12, trypsin EDTA, sodium
pyruvate, HEPES, streptomycin and penicillin-G were all from GIBCO BRL (Invitrogen Corp.,
Grand Island, NY, USA).
The isolation and fractionation procedures were performed on column chromatography carried
out on silica gel (32-63μm, Dynamic adsorbents Inc.), Sephadex LH20 (Sigma-Aldrich), or
reversed-phase C-18 (Polar bond, J. T. Baker) while the analytical TLC was carried out on silica
gel F254 aluminum sheet (20 × 20 cm, Fluka) or Silica 60 RP-18 F254S aluminum sheet (20×20
cm, Merck). Savant Speed Vac Plus SC210A Concentrator was employed to concentrate and dry
the samples. Visualization of the spots on TLC was observed under UV light at 254 or 365 nm
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and derivatized by spraying with 1% vanillin dissolved in 10% H2SO4/ethanol reagent and
heating via heat gun for the detection of phenolic compounds. All solvents used in the isolation,
fractionation and purification steps were purchased from Fisher Scientific (Fair Lawn, NJ) as
analytical grade solvents. The NMR spectra were obtained on either Varian Dual Broadband
Probe or Bruker Avance DRX spectrometer at 400 MHz for 1H experiments and 100 MHz for
13

C experiments. Using standard pulse instrument software, other 2D experiments (DEPTQ135,

COSY, HSQC, HMBC, and NOESY) were recorded. DMSO or CD3OD solvents were used as
the internal standards and residual solvents to obtain and calibrate the spectrum, respectively.
High-resolution electrospray ionization mass spectra (HR-ESI-MS) were acquired by injection
the samples directly to an Agilent Technologies 6200 series mass spectrometer in the positive
and negative ion modes. Chiroptical techniques were employed to assign the absolute
configuration using an Olis DSM 20 circular dichroism spectrophotometer (Olis, Inc.) and
confirmed by AUTOPOL IV Automatic Polarimeter (Rudolph, Hackettstown, NJ, USA) to
measure the specific rotation. Agilent Technologies Cary 630 FTIR was utilized for recording
the IR spectra each compound.
2.2.2 Culture of HepG2, MDCK-II, and hMDR1-MDCK-II cells:
HepG2 cells were grown in DMEM/F12 supplemented with 10% FBS, 2.4 g/L sodium
bicarbonate, 100 μg/mL streptomycin, and 100 U/mL penicillin-G at 37 °C, 5% CO2, and 95%
relative humidity. MDCK-II and hMDR1-MDCK-II cell lines were cultured in DMEM medium
supplemented with 10% FBS, 1% non-essential amino acids, 1% L-glutamine, 100 μg/mL
streptomycin, and 100U/mL penicillin-G at 37 °C, 5% CO2, and 95% relative humidity. Cell
lines were seeded on the apical side of a 12-well at a density of 65,000 cells/well (0.5 mL). On
the other side, basolateral contained transwell plate and 1.5 mL of medium.
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2.2.3 Plant material:
The dried mature leaves and stems of unfermented (green) A. linearis were received from South
Africa as a gift from Rooibos Limited in Clanwilliam (Ms Colette Cronje, sample #793) in
October 2014. A specimen (NCNPR # 16850) was prepared and deposited by Dr. Vijayasankar
Raman in the herbarium of NCNPR, School of Pharmacy, University of Mississippi. The
morphological and chemical properties were compared with the reference sample (NCNPR #
5488) at the NCNPR as a process for the authentication.
2.2.4 Extraction and isolation of compounds:
The dried leaves and stems of A. linearis species (1.5 Kg) were ground to a fine powder and
extracted successively by percolation process with MeOH (4 liters × 5 times) at room
temperature. The MeOH solution was then evaporated under reduced pressure at 40 °C to yield a
dried MeOH crude extract (202.8 g). An aliquot (100 g) was subjected to column
chromatography

on

silica

gel

(8

cm

×

73

cm)

and

eluted

with

ethyl

acetate/chloroform/MeOH/water gradient systems (15:8:4:1, 10:6:4:1, and 6:4:4:1) to provide
twenty parent fractions (1-20). Fr. 6 (0.95 g) was fractionated by silica gel with
chloroform/MeOH/water (8:2:0.25) to afford vitexin (5, 73.4 mg). Fr. 8 (0.27 g) was subjected
on Sephadex LH-20 (92 cm × 4 cm) with MeOH/water mixtures (1:1, 3:1, and 1:0) followed by
silica gel (102 cm × 2.7 cm) with chloroform/MeOH/water (8:2:0.25) to yield isoquercitrin (8,
76.6 mg), thermopsoside (3, 23.6 mg) and nothofagin (2, 306.6 mg). Fr. 10 (2.95 g) was applied
over Sephadex LH-20 (90 cm × 2.5 cm) with MeOH and subsequently on reversed phase silica
gel (28 cm × 2.5 cm) with water/MeOH mixtures (7:3, 3:2, and 1:1) to produce hyperoside (7, 62
mg). Aspalathin (1, 521.0 mg), isovitexin (6, 8.4 mg) and (S/R)-eriodictyol-6-C--Dglucopyranoside (11, 68.1 mg) were purified from Fr. 12 (4.33 g) by repeated column
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chromatography [Sephadex LH-20 (92 cm × 4 cm), MeOH/water (1:1, 3:1, and 1:0); silica gel
(104.5 cm × 2.7 cm), chloroform/MeOH/water (8:2:0.25); and silica gel (76 cm × 2 cm),
chloroform/MeOH/water (8:2:0.25)]. Fr. 14 (1.86 g) was chromatographed on Sephadex LH-20
(98 cm × 4.5 cm) with MeOH to obtain isoorientin (4, 90.9 mg) and syringin (12, 68.8 mg). Fr.
17 (2.37 g) was fractionated by reversed phase C-18 silica gel (47 cm × 3 cm) with water/MeOH
(7:3 and 3:2) followed by Sephadex LH-20 column (101 cm × 3.2 cm) with MeOH to purify
rutin (9, 59.6 mg) and bioquercetin (10, 136.9 mg). Structure elucidation of the isolated
compounds was performed by analysis of their spectroscopic data including 1D and 2D NMR,
circular dichroism, IR, and spectrometric analysis by HR-ESI-MS.
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2.2.4.1 Aspalathin (1):
UV (MeOH) λmax: 287.9, 226.6 nm (Figure 2-1); 13C NMR (101 MHz, DMSO-d6) δ 204.96,
165.26, 164.12, 162.11, 145.43, 143.70, 132.88, 119.37, 116.19, 115.94, 104.46, 104.08, 95.05,
81.76, 79.36, 74.02, 71.11, 70.89, 61.74, 45.97, 30.15 (Figure 2-2); 1H NMR (400 MHz,
DMSO-d6): (Figure 2-3); HR-ESI-MS (negative ion mode) m/z: 451.1605 [M-H]-, calculated
451.1241 for C21H23O11 (Figure 2-4).
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Figure 2-1: UV spectrum and chromatogram of 1, (288 nm: purity 92.94%)
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Figure 2-2: 13C NMR spectrum of 1 in DMSO

Figure 2-3: 1H NMR spectrum of 1 in DMSO
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Figure 2-4: HR-ESI-MS of 1
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2.2.4.2 Nothofagin (2):
UV (MeOH) λmax: 286.7, 226.0 nm (Figure 2-5);

13

C NMR (101 MHz, DMSO-d6) δ 205.30,

165.08, 163.86, 162.17, 155.10, 132.46, 129.69, 115.56, 104.11, 103.80, 95.04, 81.14, 78.89,
73.88, 71.04, 70.37, 61.34, 45.94, 29.79 (Figure 2-6);

1

H NMR (400 MHz, DMSO-d6):

(Figure 2-7); HR-ESI-MS (negative ion mode) m/z: 435.1598 [M-H]-, calculated 435.1291 for
C21H23O10 (Figure 2-8).
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Figure 2-5: UV spectrum and chromatogram of 2, (288 nm: purity 96.61%)
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Figure 2-6: 13C NMR spectrum of 2 in DMSO

Figure 2-7: 1H NMR spectrum of 2 in DMSO
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Figure 2-8: HR-ESI-MS of 2
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2.2.4.3 Thermopsoside (3):
UV (MeOH) λmax: 347.9, 252.3 nm (Figure 2-9);

13

C NMR (101 MHz, DMSO-d6) δ 182.25,

164.67, 162.96, 160.97, 157.11, 150.78, 148.15, 121.64, 120.92, 116.03, 109.82, 105.59, 103.35,
100.02, 99.94, 95.31, 77.07, 76.29, 73.29, 69.89, 60.99, 56.08 (Figure 2-10); 1H NMR (400
MHz, DMSO-d6): (Figure 2-11); HR-ESI-MS (negative ion mode) m/z: 461.1105 [M-H]-,
calculated 461.1084 for C22H21O11 (Figure 2-12).
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Figure 2-9: UV spectrum and chromatogram of 3, (288 nm: purity 99.60%)
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Figure 2-10: 13C NMR spectrum of 3 in DMSO

Figure 2-11: 1H NMR spectrum of 3 in DMSO
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Figure 2-12: HR-ESI-MS of 3
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2.2.4.4 Isoorientin (4):
UV (MeOH) λmax: 348.6, 269.4, 210.8 nm (Figure 2-13);

13

C NMR (101 MHz, DMSO-d6) δ

182.34, 164.13, 163.76, 161.16, 156.68, 150.18, 146.21, 121.90, 119.46, 116.54, 113.77, 109.32,
103.87, 103.28, 94.00, 82.02, 79.41, 73.53, 71.09, 70.69, 61.96 (Figure 2-14); 1H NMR (400
MHz, DMSO-d6): (Figure 2-15); HR-ESI-MS (negative ion mode) m/z: 447.1217 [M-H]-,
calculated 447.0928 for C21H19O11 (Figure 2-16).
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Figure 2-13: UV spectrum and chromatogram of 4, (355 nm: purity 81.30%)
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Figure 2-14: 13C NMR spectrum of 4 in DMSO

Figure 2-15: 1H NMR spectrum of 4 in DMSO
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Figure 2-16: HR-ESI-MS of 4
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2.2.4.5 Vitexin (5):
UV (MeOH) λmax: 337.3, 267.6, 213.8 nm (Figure 2-17);

13

C NMR (101 MHz, DMSO-d6) δ

182.55, 164.46, 163.18, 161.66, 160.83, 156.46, 129.41, 122.02, 116.34, 105.06, 104.45, 102.87,
98.67, 82.26, 79.11, 73.83, 71.33, 71.00, 61.76 (Figure 2-18); 1H NMR (400 MHz, DMSO-d6):
(Figure 2-19); HR-ESI-MS (negative ion mode) m/z: 431.1016 [M-H]-, calculated 431.0978 for
C21H19O10 (Figure 2-20).
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Figure 2-17: UV spectrum and chromatogram of 5, (355 nm: purity 90.37%)
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Figure 2-18: 13C NMR spectrum of 5 in DMSO

Figure 2-19: 1H NMR spectrum of 5 in DMSO
27

Figure 2-20: HR-ESI-MS of 5
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2.2.4.6 Isovitexin (6):
UV (MeOH) λmax: 336.7, 268.8, 212.6 nm (Figure 2-21);

13

C NMR (101 MHz, DMSO-d6) δ

182.32, 164.46, 163.90, 161.77, 161.09, 156.72, 128.86, 121.49, 116.51, 109.36, 103.58, 103.14,
94.22, 81.99, 79.46, 73.54, 71.02, 70.61, 61.88 (Figure 2-22); 1H NMR (400 MHz, DMSO-d6):
(Figure 2-23); HR-ESI-MS (negative ion mode) m/z: 431.1590 [M-H]-, calculated 431.0978 for
C21H19O10 (Figure 2-24).
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Figure 2-21: UV spectrum and chromatogram of 6, (355 nm: purity 93.80%)
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Figure 2-22: 13C NMR spectrum of 6 in DMSO

Figure 2-23: 1H NMR spectrum of 6 in DMSO
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Figure 2-24: HR-ESI-MS of 6
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2.2.4.7 Hyperoside (7):
UV (MeOH) λmax: 356.0, 254.7 nm (Figure 2-25);

13

C NMR (101 MHz, DMSO-d6) δ 177.84,

164.89, 161.59, 156.77, 156.66, 148.94, 145.23, 133.86, 122.31, 121.46, 116.43, 115.67, 104.22,
102.30, 99.25, 94.06, 76.18, 73.58, 71.63, 68.34, 60.55 (Figure 2-26); 1H NMR (400 MHz,
DMSO-d6): (Figure 2-27); HR-ESI-MS (negative ion mode) m/z: 463.0926 [M-H]-, calculated
463.0877 for C21H19O12 (Figure 2-28).
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Figure 2-25: UV spectrum and chromatogram of 7, (355 nm: purity 91.29%)
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Figure 2-26: 13C NMR spectrum of 7 in DMSO

Figure 2-27: 1H NMR spectrum of 7 in DMSO
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Figure 2-28: HR-ESI-MS of 7
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2.2.4.8 Isoquercitrin (8):
UV (MeOH) λmax: 350.4, 254.7 nm (Figure 2-29);

13

C NMR (101 MHz, DMSO-d6) δ 177.48,

163.76, 160.71, 157.17, 156.38, 148.17, 144.26, 133.84, 122.24, 121.56, 116.73, 115.60, 104.21,
102.21, 99.00, 94.11, 76.56, 76.22, 74.16, 69.48, 60.82 (Figure 2-30); 1H NMR (400 MHz,
DMSO-d6): (Figure 2-31); HR-ESI-MS (negative ion mode) m/z: 463.1224 [M-H]-, calculated
463.0877 for C21H19O12 (Figure 2-32).
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Figure 2-29: UV spectrum and chromatogram of 8, (355 nm: purity 97.29%)
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Figure 2-30: 13C NMR spectrum of 8 in DMSO

Figure 2-31: 1H NMR spectrum of 8 in DMSO
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Figure 2-32: HR-ESI-MS of 8
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2.2.4.9 Rutin (9):
UV (MeOH) λmax: 352.3, 255.3 nm (Figure 2-33);

13

C NMR (101 MHz, DMSO-d6) δ 177.78,

164.86, 161.65, 157.05, 156.91, 148.90, 145.22, 133.73, 122.06, 121.62, 116.71, 115.69, 104.31,
101.67, 101.20, 99.24, 94.12, 76.89, 76.34, 74.53, 72.30, 71.01, 70.83, 70.45, 68.70, 67.46, 18.19
(Figure 2-34); 1H NMR (400 MHz, DMSO-d6): (Figure 2-35); HR-ESI-MS (negative ion mode)
m/z: 609.1870 [M-H]-, calculated 609.1456 for C27H29O16 (Figure 2-36).
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Figure 2-33: UV spectrum and chromatogram of 9, (355 nm: purity 94.24%)
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Figure 2-34: 13C NMR spectrum of 9 in DMSO

Figure 2-35: 1H NMR spectrum of 9 in DMSO
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Figure 2-36: HR-ESI-MS of 9
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2.2.4.10 Bioquercetin (10):
UV (MeOH) λmax: 352.9, 255.3 nm (Figure 2-37);

13

C NMR (101 MHz, DMSO-d6) δ 177.80,

165.03, 161.61, 156.87, 156.86, 148.98, 145.26, 133.92, 122.33, 121.51, 116.50, 115.67, 104.21,
102.58, 100.47, 99.31, 94.13, 74.04, 73.51, 72.38, 71.57, 71.05, 70.87, 68.73, 68.54, 65.73, 18.35
(Figure 2-38); 1H NMR (400 MHz, DMSO-d6): (Figure 2-39); HR-ESI-MS (negative ion mode)
m/z: 609.1883 [M-H]-, calculated 609.1456 for C27H29O16 (Figure 2-40).
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Figure 2-37: UV spectrum and chromatogram of 10, (355 nm: purity 90.06%)
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Figure 2-38: 13C NMR spectrum of 10 in DMSO

Figure 2-39: 1H NMR spectrum of 10 in DMSO
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Figure 2-40: HR-ESI-MS of 10
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2.2.4.11 (S/R) Eriodictyol-6-C--D-glucopyranoside (11):
UV (MeOH) λmax: 384.0, 288.5, 214.4 nm (Figure 2-41);

13

C NMR (101 MHz, DMSO-d6) δ

197.05, 166.10, 162.97, 162.12, 145.75, 145.26, 129.88, 118.76, 115.90, 114.52, 105.45, 101.96,
95.29, 81.30, 79.01, 78.61, 78.58, 73.23, 70.59, 61.60, 41.94 (Figure 2-42); 1H NMR (400 MHz,
DMSO-d6): (Figure 2-43); HR-ESI-MS (negative ion mode) m/z: 449.1418 [M-H]-, calculated
449.1084 for C21H21O11 (Figure 2-44).
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Figure 2-41: UV spectrum and chromatogram of 11
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Figure 2-42: 13C NMR spectrum of 11 in DMSO

Figure 2-43: 1H NMR spectrum of 11 in DMSO
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Figure 2-44: HR-ESI-MS of 11
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2.2.4.12 Syringin (12):
UV (MeOH) λmax: 382.7, 264.5, 219.9 nm (Figure 2-45);

13

C NMR (101 MHz, MeOH-d4) δ

152.94, 134.47, 133.88, 129.87, 128.69, 104.07, 103.97, 76.94, 76.41, 74.33, 69.93, 62.20, 61.18,
55.67 (Figure 2-46); 1H NMR (400 MHz, MeOH-d4): (Figure 2-47); HR-ESI-MS (negative ion
mode) m/z: 407.1403 [M-Cl]-, calculated 407.1109 for C17H23O9 (Figure 2-48).
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Figure 2-45: UV spectrum and chromatogram of 12, (288 nm: purity 90.06%)
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Figure 2-46: 13C NMR spectrum of 12 in CD3OD

Figure 2-47: 1H NMR spectrum of 12 in CD3OD
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Figure 2-48: HR-ESI-MS of 12
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2.2.5 Inhibitory activity with recombinant CYP assay:
The assay to determine the inhibitory activity of test samples on the metabolic activity of CYPs
was performed under similar conditions as earlier reported.(Manda, Dale, et al., 2014) The
MeOH extract of A. linearis and its constituents along with positive controls were serially diluted
in a solution (100 µL) of cofactors mix, CYP proteins (0.05 mg of protein/mL), and G-6-PDH to
achieve six concentrations ranging from 0.1 to 100 µg/mL for the extract and 0.1 to 100 µM for
the pure compounds. DMSO was used as the vehicle control. Initial readings were recorded to
report the inherent fluorescence then the plates were incubated at 37 °C for 10 min. Initiation the
enzymatic reaction was achieved by the addition of the enzyme substrate mixture (100 µL)
followed by incubation for 45 min (according to instructions provided for each enzyme). The
incubation mixture with a total volume of 200 µL was transferred to a 96-well microplate.
Termination of the enzymatic reaction was performed by the addition of 75 µL of ice cold
acetonitrile/0.5M Tris base (80:20). For each substrate, fluorescence was measured on a
Spectramax M5 plate reader (Molecular Devices, Sunnyvale, CA, USA) at specified excitation
and emission wavelengths. IC50 values were calculated by profiling the tested concentrations
against observed enzyme inhibition (%).
2.2.6 Pregnane-X receptor (PXR) Modulation by luciferase reporter gene assay:
The PXR modulation assay was conducted in HepG2 cells transiently transfected with pSG5PXR (25 µg) and PCR5 plasmid DNA (25 µg) via electroporation at 180 V, 1 pulse for 70 ms as
described earlier.(Manda, Avula, et al., 2014) In brief, the aforementioned cells were seeded in
96-well plates at a density of 50,000 cells per well. After the cells reached 90% confluency upon
24 hours, the samples were added at several concentrations (0.3-30 μM for controls and isolated
compounds; 1-60 μg/mL for the MeOH extract). After 24 h incubation, the media were aspirated
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and 40 µL of luciferase reagent (Promega Corporation, Madison, WI, USA) was added to each
well followed by measuring the luminescence on Spectramax M5 plate reader (Molecular
Devices, Sunnyvale, CA, USA). Compared with vehicle-treated cells, the fold induction in
luciferase activity was calculated for the sample treated cells.
2.2.7 Assay for P-glycoprotein Inhibition by Calcein-AM Uptake in Parental and
Transfected MDCK-II Cells:
The efflux activity of P-gp was determined for the test samples as mentioned earlier.(Manda et
al., 2016) 70,000 cells/well in 200 µL of culture medium were cultured in 96-well plates. After
24 h, the media were changed and left for 48 h. The test samples and the positive control
(cyclosporine A 0.4–100 µM) were added to the cells at varying concentrations (0.4–100 µg/mL)
in 50 µL of transport buffer and incubated at 37 °C for 10 min. DMSO was used as the negative
control. As a fluorescent substrate of P-gp, Calcein-AM (1 µM) was added to the plates.
Immediately, the plates were placed on Spectramax to read the fluorescence up to 1 h at 15-min
intervals at excitation and emission wavelengths of 485 and 530 nm, respectively. EC50 was
determined by plotting the increase (%) in calcein-AM uptake against the log concentration to
obtain the concentrations that caused 50% increase using GraphPad Prism Software V.7.0
(GraphPad Software, Inc., San Diego, CA, USA).
2.2.8 RT-PCR analysis of CYP3A4, CYP1A2, CYP2C9, and P-gp mRNA:
The validated forward and reverse primers for CYP3A4 (qHsaCID0012316), CYP1A2
(qHsaCID0015160), CYP2C9 (qHsaCED0044817), and P‐gp (qHsaCED0002291) were
purchased from Bio-Rad Laboratories (Hercules, CA, USA). Transfected HepG2 cells were
cultured into 6-well plate at a density of 50,000 cells per well and cultivated for 24 h (> 90%
confluency). After that, cells were treated with several concentrations of test samples (12.5-50
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μg/mL for the MeOH extract; 0.3-30 μM for isolated phytochemicals; 30 μM for positive
controls). After 48 h, the cells were washed with PBS, and the total RNA was extracted using the
Quick-start protocol (Qiagen®). RT-PCR was carried out in a 96-well plate by a CFX connect
real-time PCR detector system (Bio-Rad). The gene expression of CYP3A4, CYP1A2, CYP2C9
and P-gp was quantified relatively and normalized to housekeeping gene HPRT1
(qHsaCID0016375) as control gene. Compared with vehicle-treated cells, the fold induction in
mRNA expression for treated cells was calculated.
2.3

Results:

2.3.1 Isolation and structure elucidation:
Phytochemical investigation of the MeOH extract of A. linearis mixed parts comprising leaves
and stems resulted in the isolation and characterization of 11 flavonoid glycosides including two
dihydrochalcone derivatives, aspalathin(B. H. Koeppen & Roux, 1965) (1) and nothofagin(W. E.
Hillis & Inoue, 1967) (2), four flavone derivatives, thermopsoside(Kattaev & Nikonov, 1973)
(3), isoorientin(B. H. Koeppen, 1965) (4), vitexin(W. Hillis & Horn, 1965) (5) and isovitexin(W.
Hillis & Horn, 1965) (6), three flavonol derivatives, hyperoside(Markham et al., 1978),
isoquercitrin(Markham et al., 1978) (8), rutin(B. Koeppen et al., 1962) (9) and
bioquercetin(Rastrelli et al., 1995) (10), one flavanone derivative, (R/S)-eriodictyol-6-C--Dglucopyranoside(Marais

et

al.,

2000)

(11),

and

one

phenylpropanoid

derivative,

syringin(Sutarjadi et al., 1978) (12). Structure elucidation was mainly achieved by spectroscopic
data analysis including 1D and 2D NMR (1H, 13C, DEPTQ135, COSY, HSQC, and HMBC), and
confirmed by HR-ESI-MS data (Figure 2-49). Based on NMR data, the purities of
phytoconstituents 1-12 were approximately 90-95%. The stereochemistry of 11 was determined
as (S) configuration due to a negative cotton effect at 284 nm in circular dichroism (CD)
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experiment.(Li et al., 2014) UHPLC‑UV Chromatograms of standards mixture and authenticated
plant sample (#16850) at 288 nm are illustrated in Figure 2-50.
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Figure 2-49: Chemical structures of isolated phytoconstituents 1-12 from Aspalathus linearis
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Figure 2-50: UHPLC‑UV Chromatograms of standards mixture and authenticated plant sample
(#16850) at 288 nm

2.3.2 Inhibition of CYP isoforms by the MeOH extract of A. linearis and its isolated
compounds:
The inhibitory effects of test samples on the catalytic activity of CYP isoforms were measured. A
decrease in the formation of the respective metabolites was calculated, and the IC50 value
(concentration responsible for a 50% decrease in activity) was determined from concentration
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response curves. The crude MeOH extract of A. linearis demonstrated significant inhibition (IC50
< 20 μg/mL, Table 2-1) of the major human CYP450 isoforms (CYP3A4, CYP1A2, CYP2D6,
CYP2C9, and CYP2C19) which are responsible for the metabolism of 80% of the clinical drugs.
The strongest inhibition was observed for CYP3A4 (IC50 1.7 ± 0.1 µg/mL) followed by
CYP2C19 (IC50 4 ± 0.3 µg/mL). It was interesting to note that the activity of CYP3A4 was
inhibited by almost all isolated secondary metabolites in varying degrees with the most potent
inhibition exerted by isovitexin (IC50 3.4 ± 0.2 µM), vitexin (IC50 4 ± 0.3 µM) and thermopsoside
(IC50 6 ± 0.5 µM). In addition, hyperoside (9 ± 0.3 µM) and thermopsoside (9.5 ± 0.2 µM)
exhibited the strongest inhibition for CYP2C19 isozyme. Rutin, a common flavonoid also
present in several other plant species, was found to be responsible for the CYP1A2 inhibition
while vitexin, isovitexin, isoorientin and thermopsoside seem to be the major contributors for
CYP2D6 and CYP2C9 inhibition as shown in Table 2-1
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Table 2-1: The inhibitory activity of the MeOH extract and isolated compounds from A. linearis
on CYP isozymes.

CYP3A4

CYP1A2

Test sample
A. linearis extract

CYP2D6

CYP2C9

CYP2C19

10 ± 0.3

4 ± 0.3

IC50 µg/mL
1.7 ± 0.1

19 ± 1.1

20 ± 1.8
IC50 µM

Aspalathin

90 ± 3.8

-

-

> 100

> 100

Nothofagin

88 ± 3.4

-

-

> 100

> 100

Isovitexin

3.4 ± 0.2

-

56 ± 1.2

57 ± 1.2

55 ± 1.6

Thermopsoside

6 ± 0.5

> 100

12 ± 0.3

32 ± 1.4

9.5 ± 0.2

Syringin

10 ± 1.2

-

-

> 100

> 100

Isoorientin

10 ± 0.2

> 100

40 ± 1.6

> 100

24 ± 0.2

Rutin

45 ± 2.4

85 ± 2.5

-

-

57 ±1.3

Bioquercetin

56 ± 1.8

-

-

-

> 100

Hyperoside

15 ± 0.4

-

-

-

9 ± 0.3

Vitexin

4 ± 0.3

-

> 100

8 ± 0.2

13 ± 0.3

44 ± 1.7

-

> 100

> 100

> 100

Isoquercitrin

61± 1.2

-

-

> 100

21 ± 0.3

Ketoconazole*

0.04 ± 0.001

eriodictyol-6-C--Dglucopyranoside

Furafylline*

1.5 ± 0.1

Quinidine*

0.05 ± 0.001

Sulfaphenazole*

3 ± 0.3

Tranylcypromine*

1.2 ± 0.1

(-) indicates the lack of inhibition, (*) indicates the positive control for respective CYP450
isozyme. The data are represented as mean ± SD of three independent experiments.
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2.3.3 PXR modulation by the MeOH extract of A. linearis and its isolated compounds:
PXR reporter gene assay is a reliable method to assess the CYP induction potential of
xenobiotics. It was established to screen CYP450 inducers based on the activation of PXR
determined in HepG2 cells. The MeOH extract was found to increase the activity of PXR in
comparison to the vehicle. The effect was concentration dependent as shown in Figure 2-51. Of
the 12 isolated secondary metabolites tested, thermopsoside and hyperoside showed about a twofold activation of PXR at 30 µM while the two major dihydrochalcone derivatives, aspalathin
and nothofagin displayed a moderate activation at 10 µM (1.56 and 1.38 respectively)
(Figure 2-51). Rifampicin (10 µM) showed an activation of 4.09 in the same assay (or under
similar assay conditions).
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Figure 2-51: Effect of Aspalathus linearis MeOH extract and its constituents on PXR
determined by reporter gene assay: Values are fold increase in PXR activity compared to DMSO
control. An increase of 1.5 fold or more means there is an increase of 50% or more. The extract
showed a concentration-dependent effect on PXR. The MeOH extract was tested at
concentrations of 30, 10, and 3 μg/mL whereas the pure compounds, were tested at 30, 10, and 3
μM. * P < 0.05, ** P < 0.01, and *** P < 0.001, determined by one way ANOVA, followed by
Bonferroni’s post-tests. The data are represented as mean ± SD of triplicate measurements in
three independent experiments.
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2.3.4 P-glycoprotein inhibition by the MeOH extract of A. linearis and its isolates:
P-glycoprotein (P-gp) is recognized as one of the efflux transporters in many tissues, and P-gp
inhibition is responsible for multiple herb-drug interactions. The efflux activity of P-gp was
evaluated for the MeOH extract and isolated phytochemicals, and none of the test samples
inhibited P-gp activity in the inhibition assay at 100 µg/mL (data not shown).
2.3.5 mRNA expressions of major CYP isoforms and P-gp:
The PXR reporter gene assay results demonstrate that A. linearis extract and its constituents
(aspalathin, nothofagin, thermopsoside, and hyperoside) caused an induction in PXR
transcriptional activity. To further confirm if this increase in PXR activity resulted in the
increased expression of four major downstream target genes: CYP3A4, CYP1A2, CYP2C9 and
P-gp, we carried out real‐time reverse transcriptase‐polymerase chain reaction (RT‐PCR)
analysis for the gene expression. Unexpectedly, the extract showed marginal effect on expression
of CYP genes compared to the vehicle. However, aspalathin, a dihydrochalcone derivative,
showed a significant induction (1.81 fold) in CYP3A4 expression at a concentration of 30 µM.
Similarly, an increase of 1.64 and 1.42‐fold was observed at a concentration of 30 μM of
nothofagin for CYP1A2 and CYP3A4 expression, respectively. On the other hand, compounds
such as hyperoside and thermopsoside activated PXR but have marginal effects on expression of
CYP450 target genes (Table 2-2). In addition, the expression of P-gp mRNA was not affected by
the extract or the isolated compounds tested in this study (data not shown).
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Table 2-2: Effect of isolates on the expression of CYPs: Values are folds increase in mRNA
expression compared to DMSO control. An increase of 1.5 fold or more means there is an
increase of 50% or more.

Fold increase in mRNA expression#
Test sample

CYP1A2

CYP3A4

CYP2C9

A. linearis extract

1.14 ± 0.14

NA

NA

Aspalathin

NA

1.81 ± 0.18*

NA

Nothofagin

1.64 ± 0.33*

1.42 ± 0.57

NA

eriodictyol-6-C--D-glucopyranoside

NA

1.32 ± 0.17

NA

Thermopsoside

NA

1.16 ± 0.13

NA

Hyperoside

NA

1.11 ± 0.04

NA

Omeprazole

5.78 + 0.7
2.1 + 0.8

7.6 + 1.1

Rifampicin
#

Fold increase in mRNA expression at 30 µg/mL of extract and 30 µM of pure compounds or

drug controls The data are represented as mean ± SD of triplicate measurements in three
independent experiments. *P < 0.05, determined by one way ANOVA, followed by Bonferroni’s
post-tests. NA = no activation
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2.4

Discussion:

Due to the ability to biosynthesize unique and rare secondary metabolites, rooibos tea is known
for its hypoglycemic activity.(Kawano et al., 2009; Muller et al., 2012) To the best of our
knowledge, aspalathin (acyclic dihydrochalcone) was isolated from Aspalathus linearis species
as the sole natural source. Additionally, nothofagin was found to be a rare compound derived
from A. linearis, the heartwood of Nothofagus fusca previously, and lately from the bark of a
Chinese medicinal plant Schoepfia chinensis.(E. Joubert et al., 2008) Yet, aspalathin and
nothofagin recently were detected in closely related and endangered species, Aspalathus pendula
(the golden tea).(Johnson et al., 2018; Stander et al., 2017) In addition to aspalathin and
nothofagin, phytochemical investigation of A. linearis species in this study afforded ten
additional phenolic secondary metabolites. This is the first report of the isolation of
thermopsoside from A. linearis.
Phytochemicals derived from natural origins are pivotal agents for treating a range of illnesses
when administered orally or applied topically. Simultaneously, they could be exploited for
further optimization as a promising natural lead nucleus to synthesize potent therapeutic analogs.
The quest to find a bioactive botanical, either as a standardized extract or a single natural
compound is a core research domain for a number of research laboratories. However,
investigating the safety profile for these pharmacological candidates is as substantial as seeking
for biological activity. Limited information is available in the literature related to the safety
profile of A. linearis. With the rapid increase in its global use, the possibility of herb-drug
interaction needs to be explored.
The UHPLC-MS and the fragmentation patterns indicated that the most abundant components of
A. linearis were C-glycosides. The neutral mass loss of hexose equals 120 Da usually observed
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compared with the 162 Da with the O-counterparts. Also, the chemical shift value for the
anomeric carbon, which appears at the upfield region of the NMR spectra, aids in the
identification

of
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compounds

flavonoids),

(supplementary data).
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flavonoid

Unlike

classical

derivatives

have

flavonoids
superior

characteristic features. For instance, their glycone moiety is attached via the C-1” directly to the
flavonoid backbone, usually at the C-6 or C-8 position of the A ring as shown in Figure 2-49.
This feature affords them the ability to resist the hydrolysis and be absorbed intact in the colon.
Therefore, C-glycosides have exclusive biological activities compared with their counterparts, Oglycosides. During metabolism, they might react differently with the liver enzymes as well.(Zeng
et al., 2013)
Quantitative analysis by HPLC-UV previously indicated that the abundant phytochemicals in
aqueous unfermented rooibos extract were aspalathin followed in order by isoorientin, orientin,
rutin, isovitexin, vitexin, and isoquercitrin.(Bramati et al., 2003) As shown in Figure 2-50,
UHPLC-UV chromatogram at 288 nm reveals that aspalathin remains the main phytochemical
present in MeOH extract of unfermented rooibos in agreement with the previous study.
Additionally, a pool of minor compounds was detected alongside aspalathin, and successful
isolation of some components was achieved. Nevertheless, the absence of orientin in this study
might be justified by the effects of fractionation conditions employed during the phytochemical
investigation or accidental loss in other fractions.
In the present study, the effect of MeOH extract as well as isolated phytochemicals from A.
linearis species were evaluated on the major human CYP450 isozymes. Accordingly, CYP3A4
and CYP2C19 enzyme activity was found to be inhibited potently by the MeOH extract.
However, the inhibition of CYP3A4 was not very strong by two major compounds, aspalathin
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(IC50 = 90 ± 3.8 µM) and nothofagin (IC50 = 88 ± 3.4 µM). These results are in agreement with a
recent study performed on aspalathin and fermented rooibos extract.(Patel et al., 2016) This
observation also indicates that other minor compounds present in the unfermented rooibos
extract could synergistically account for the inhibitory activity of the MeOH extract towards
CYP3A4. On the contrary, these two major components increased PXR activity to 1.56 and 1.38
fold, respectively. Moreover, further mRNA expression studies in HepG2 cells displayed
significant increase in CYP3A4 gene expression after treatment with aspalathin and nothofagin
(30 µM). Our findings suggest that the inhibitory effect of these compounds on the activity of
CYP3A4 isozyme is a negative compensatory mechanism for the increase of mRNA at lower
concentrations. Therefore, further studies should be carried out to translate the in vitro
experiments to in vivo studies in animal models to observe the overall effect.
Flavone derivatives including vitexin, isovitexin, isoorientin, and thermopsoside exhibited
inhibitory activities on CYP3A4 and CYP2C19. Except for isoorientin, they also displayed
inhibitory action on CYP2C9 enzyme. Isoorientin, C-glucosyl flavone, has an additional hydroxy
group attached to ring B which potentially played a role in reducing the inhibitory activity of this
component on CYP2C9 compared to vitexin, isovitexin and thermopsoside. The most potent
inhibitory activities in this study were observed with isovitexin on CYP3A4, vitexin on
CYP2C9, and thermopsoside on CYP2C19. Parallel pharmacological effects including
antihypertensive and anti-inflammatory activities for vitexin and isovitexin were previously
reported because of the structural resemblance. The distribution of vitexin and isovitexin are
evident in a wide range of plants such as Aspalathus pendula, Mimosa pudica, Passiflora
species, wheat leaves, and bamboo. The primary source and highest concentration of vitexin was
determined in the leaves of Crataegus pinnatifida (9.53 mg/g).(He et al., 2016) Thermopsoside,
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on the other hand, was isolated for the first time from Thermopsis alterniflora, and reported in
other species including the fruits of Rhus parviflora and aerial part of Lycopus lucidus.(Kattaev
& Nikonov, 1973; Malik et al., 2002; Shrestha et al., 2012)
Bioactive C-glycoside flavones such as isovitexin and vitexin are structurally similar except
for the position of the sugar attachment. Both regioisomers inhibited CYP3A4 enzyme activity to
a similar extent (IC50 of 4.0 ± 0.3 and 3.4 ± 0.2 µM, respectively). On the other hand, their ability
to inhibit CYP2C19 and CYP2C9 activities was dissimilar. While the former exhibited the
inhibitory activity with an IC50 of 55.0 ± 1.6 µM and 57.0 ± 1.2 µM, respectively, the latter
inhibited CYP2C19 isozyme with an IC50 of 13.0 ± 0.3 µM and CYP2C9 with an IC50 of 8.0 ±
0.2 µM. According to this result, it is possible that the CYP2C family has a distinguished binding
site which plays a substantial role in this effect providing higher selectivity towards vitexin
compared with isovitexin. Preceding in vivo studies indicated that vitexin could inhibit both
CYP3A1 and CYP2C11 but has no effect on CYP1A2 in rats.(Wang et al., 2015) Our in vitro
study also confirms that CYP1A2 enzyme activity was not affected. We report for the first time
the potent and selective inhibition of CYP3A4 (4.0 ± 0.3 µM), CYP2C9 (8.0 ± 0.2 µM), and
CYP2C19 (13.0 ± 0.3 µM) isoforms by vitexin.
For the tested flavonols (isoquercitrin, bioquercetin and rutin), CYP3A4 isozyme was found
to be inhibited with an IC50 ranging from 45-61 μM. Among these three tested flavonols,
bioquercetin showed a weak inhibitory activity (>100 μM) on CYP2C19. It is possible that the
type of glycone moiety, galactopyranoside, contributed to reducing the inhibitory activity of
bioquercetin compared with the other two compounds. As mentioned earlier, O-glycoside
flavonoids are prone to hydrolysis compared to C-glycoside counterparts. Even though the
flavonoid disaccharide epimers such as rutin and bioquercetin show different in vitro IC50 values,
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they are expected to exert similar inhibitory effects in the animal model. This effect could be a
consequence of the conversion of the aforementioned flavonols to flavonol aglycone derivative,
quercetin. The latter was extensively evaluated and found to inhibit several CYP isozymes
including CYP3A4, CYP2D6 and CYP2C9 based on prior in vivo studies.(Song et al., 2013;
Valentova et al., 2014)
Multiple endogenous substrates and exogenous xenobiotics are predominantly metabolized
and biosynthesized by cytochrome P450. Moreover, these heme-containing mono-oxygenases
are exclusively responsible for the conversion of the inactive prodrug to the pharmacologically
active metabolites in the human body. Both CYP inducers and inhibitors interact with CYP
isozymes and interfere with CYP substrates in the binding site.(Denisov et al., 2005) While CYP
inhibitors can intensify the toxicity profile of other medicines being accumulated in the body,
CYP inducers have the ability to eliminate the drugs from the biological system rapidly resulting
in diminished activity. Clinically, two case reports indicated the potential hepatotoxicity
associated with rooibos tea in patients who experienced elevated liver enzymes after ingestion,
and they recovered liver functions after ceasing.(Engels et al., 2013; Sinisalo et al., 2010) The
possibility of rooibos constituents reacting with CYP enzymes leading to hepatotoxicity cannot
be disregarded. A previous study indicated that concurrent consumption of fermented rooibos
extract exhibited antagonistic effects with antibacterial agents such as ciprofloxacin and
gentamicin against Gram-negative pathogen (E. coli), and antifungal therapy, amphotericin B,
against yeasts (C. albicans and C. neoformans).(Hübsch et al., 2014) Another study determined a
significant serum concertation reduction of midazolam in rats when consumed in conjunction
with rooibos tea.(Matsuda et al., 2007) Therefore, determination of components potentially
responsible for rooibos interaction with clinical drugs via CYP enzymes is pivotal. In conclusion,
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phytochemical investigation of unfermented A. linearis in this study yielded 12 secondary
metabolites which were examined for potential herb-drug interactions. The current results
demonstrated that a high intake of nutraceuticals containing rooibos extracts might lead to
possible interactions when concomitantly ingested with medicines which are metabolized by
CYP enzymes. On the basis of the former and current studies which indicated the mechanistic
potential for rooibos tea extract and phytochemicals to affect drug metabolism, further in vivo
interaction studies with clinical treatments are warranted to support the findings and highlight the
clinical significance.

66

67

68

3

CHAPTER 3:

CHEMICAL FINGERPRINT PROFILE AND COMPREHENSIVE
QUANTITATIVE ANALYSIS OF PHENOLIC COMPOUNDS FROM SOUTH
AFRICAN ROOIBOS TEA (ASPALATHUS LINEARIS) AND DIETARY
SUPPLEMENTS USING UHPLC-PDA-MS

Abstract:
Aspalathus linearis (Burm.f.) R.Dahlgren, commonly known as rooibos tea, was consumed
traditionally by the indigenous South African inhabitants as an herbal remedy. Beside
antioxidant properties, it displays estrogenic, anti-allergic, anti-spasmodic, and hypoglycemic
activity. An ultra-high-performance liquid chromatography method was developed for the
determination of 14 chemical constituents from leaves and stems of A. linearis. The efficient
separation was performed within 30 min with a temperature of 30°C by using C-18 column as
the stationary phase and water/acetonitrile as the mobile phase both containing 0.05% formic
acid gradient system. The method validation for linearity, repeatability, limits of detection, and
limits of quantification was achieved. The limits of detection from 1-5 μg/mL was reported for
the phenolic compounds (1-14) in this study. The photodiode array detector at 288 nm
wavelengths was recruited for quantification. The phenolic compounds were detected in the
range from 1.50- 9.85 % in twenty-one dietary supplements with higher content observed for the
unfermented products. The data suggests four C-glucosyl flavonoids to be employed as quality
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markers for nutraceuticals claims to contain A. linearis; two dihydrochalcones, aspalathin (6) and
nothofagin (13) alongside with two flavanones, (S)-eriodictyol-6-C--D-glucopyranoside (2) and
(R)-eriodictyol-6-C--D-glucopyranoside (3). The characterization and confirmation of
components from plant samples and dietary supplements claimed to contain A. linearis was
achieved by LC-ESI-MS. Extractive ion monitoring with the positive, [M+ H]+ and [M+ Na]+,
and negative, [M− H]− and [M – H+ HCO2H]− ion modes was involved for this purpose. The
optimized method was robust and suitable for chemical fingerprint analysis of A. linearis and
simple, economical and rapid for quality control.
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3.1

Introduction:

The Aspalathus genus belongs to the second largest plant family, Leguminosae, and comprises
more than 270 plant species. Interestingly, Aspalathus linearis (Burm.f.) R.Dahlgren, commonly
known as rooibos tea, is declared as the only edible species identified so far. It is a leguminous
shrub endemic to the western parts of the Cape region in South Africa.(E. Joubert & de Beer,
2011; Krafczyk & Glomb, 2008) It grows naturally in the Cederberg Mountains encompassing
the Citrusdal, Clanwilliam and Nieuwoudtville regions. These regions are considered as the
home of rooibos tea and the heart of the rooibos tea industry. The leaves and stems are used for
the production of the enjoyable rooibos drink since it contains no caffeine and minimal levels of
tannin. Beside antioxidant properties, it displays estrogenic, anti-allergic, anti-spasmodic, and
hypoglycemic activity.(Gilani et al., 2006; Johnson et al., 2018; Kawano et al., 2009; McKay &
Blumberg, 2007; Shimamura et al., 2006; Son et al., 2013) Rooibos tea is enjoyed in more than
37 countries, and elicited attention in the developed countries and the scientific community
recently as a health beverage. As a consequence, prices spiked dramatically between 2010 and
2014. Additionally, a recent report by the Swiss Business Hub South Africa stated that rooibos
appears to be headed towards becoming the second most commonly consumed beverage tea in
the world after ordinary tea (Camellia sinensis).(E. Joubert & de Beer, 2011) The oxidation
mechanism is primarily responsible for the fermentation process which determines the
chemotaxonomic properties and alters the identity of the phytochemical constituents, nutritional
value, and yields. Two types of rooibos are available, unfermented (green) and fermented
rooibos tea (red).(E. Joubert & de Beer, 2011; Krafczyk et al., 2009; Marais et al., 2000)
The main content in the leaves and stems of A. linearis (rooibos tea) is the phenolic constituents
including chalconoids, flavonoids, and phenylpropanoids. Currently, there is no standardization
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for the aspalathin content. Some companies use the total orientin and isoorientin content as a
standard to be higher than 0.5%. However, quantitative analysis for rooibos flavonoids often
deals with the major constituents and rely heavily on four compounds; aspalathin, nothofagin,
orientin, and isoorientin.(Schulz et al., 2003) Others limited the quantification to the major
compounds alongside with total polyphenolic content and total antioxidant activity which are
exploited as quality indicators in some countries such as the USA.(Elizabeth Joubert & de Beer,
2012) Taking into account that the flavone-6-C-glycoside has a specific clear loss of water in
mass sepctrometry in the negative mode(Waridel et al., 2001), elutes earlier than flavone-8-Cglycoside(Philbin & Schwartz, 2007), and has a distinctive UV absorbance spectrum (shoulder)
at 267 nm(Iswaldi et al., 2011), some studies distinguished between the regioisomers such as
orientin and isoorientin or vitexin and isovitexin, metabolites of aspalathin and nothofagin
respectively, leading to efficient separation.(Bramati et al., 2002, 2003) However, these studies
could not resolve the overlapping peaks for the diastereomers such as hyperoside and
isoquercitrin leading to incomplete separation and providing total quantification for these
diasteromeric flavones. Moreover, it is demonstrated that rutin content in these studies have been
erroneous since the rooibos has quercetin-3-O-robinobioside (bioquercetin) which is a
diastereomer to the rutin and was not discriminated during the quantification.(Beelders, Kalili, et
al., 2012) Others have focused their work only for characterization of the phenolic compounds in
aqueous and ethanolic extracts based on proposed structures interrogated by tandem mass
spectrometry.(Iswaldi et al., 2011) A two-dimensional chromatographic method was developed
to overcome the one dimensional counterpart issues such as the difficulty of separation and
characterization of phenolic compounds in rooibos tea leading to phenolic profiling with a total
analysis time of 17 hours.(N. A. Walters et al., 2017) A new technique, near-infrared (NIR)
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spectroscopy has been developed to analyze rooibos tea phenolics to discriminate effectively
between fermented and unfermented rooibos tea.(Schulz et al., 2003) Also, a cost-effective
capillary electrophoresis method has been exploited for quantitative analysis with low sensitivity
and robustness compared with conventional HPLC method.(Arries et al., 2017) On the other
hand, different ecotypes have been investigated from two different species, A. linearis and an
endangered species, A. pendula.(Stander et al., 2017) There are two comprehensive quantitative
analyses on rooibos tea which were conducted by the same research group utilizing a set of
standards.(Beelders, Sigge, et al., 2012; Nico A. Walters et al., 2017) However, the semiquantitave analysis was applied for these studies for the flavanones and quercetin-3-Orobinobioside affecting the validity and reliability of the method to quantify these major
compounds for rooibos tea products. Herein, lacking the standards, specifically the most
abundant compounds of fermented rooibos tea, hampered the suitability for the accurate
quantitative analysis. In addition, the aqueous extract was mostly used to simulate the tea
ingested. However, an hydroalcoholic solvent was deemed to be substantial because of their
ability to extract compounds from the rooibos tea with higher abundance values. Exploiting an
array of well-characterized pure compounds as quality markers, isolated previously from an
authenticated sample of A.linearis, will develop a robust method which serves as a guideline for
chemical fingerprint profile and achieves an accurate quantitative analysis of rooibos tea
samples.
Besides gaining popularity all over the world, and the fermentation process which alters
remarkably the chemical constituents of products, the assessment of the safety profile for the
rooibos tea in our previous study highlighted that the extract and its secondary metabolites alter
the activity of CYP450 isozymes, leading to potential herb-drug interaction. In our continued
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quest to explore the quality and safety of botanical ingredients, we aim in this study to reexamine
the phenolic profile of the rooibos tea via developing and validating robust, suitable, economic
and straightforward analytical fingerprinting approaches which potentially aid in the
identification and quantification of phytochemicals, and authentication of the rooibos tea samples
for quality assurance.
The current study was intended for the qualitative and quantitative analysis of 14 phenolic
glycosides; two dihydrochalcones, five flavones, four flavonols, two flavanones, and one phenyl
propanoid of Aspalathus linearis using ultra-high-performance liquid chromatographyphotodiode array-mass spectrometry (UHPLC‑PDA‑MS). The method is also applied to dietary
supplements claiming to contain A. linearis. The 14 standard compounds used as chemical
markers were syringin (1), (S)-eriodictyol-6-C--D-glucopyranoside (2), (R)-eriodictyol-6-C-D-glucopyranoside (3), isoorientin (4), orientin (5), aspalathin (6), vitexin (7), bioquercetin (8),
hyperoside (9), isovitexin (10), rutin (11), isoquercitrin (12), nothofagin (13) and thermopsoside
(14) as illustrated in Figure 3-1.
3.2

Materials and methods:

3.2.1 Chemicals and plant samples:
Secondary metabolites (1-14) were previously isolated and elucidated from the authenticated
plant material #16850 at the National Center for Natural Products Research (NCNPR).(Fantoukh
et al., 2019) The purity of the components was determined based on the 1H NMR spectrum and
HPLC chromatogram. The dried mature leaves and stems of unfermented (green) A. linearis
were received from South Africa as a gift from Rooibos Limited in Clanwilliam (Ms. Colette
Cronje, sample #793) in October 2014. A specimen (NCNPR # 16850) was prepared and
deposited by Dr. Vijayasankar Raman in the herbarium of NCNPR, School of Pharmacy,
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University of Mississippi. The morphological and chemical properties were compared with the
reference sample (NCNPR # 5488) at the NCNPR as a process for the authentication. Twentyone brands of dietary supplements listed as containing A. linearis were purchased online
(Table 3-1). All samples were assigned unique identifiers, and their representative samples were
deposited in the botanical repository of NCNPR in the University of Mississippi (Figure S 1).
The solvents were purchased from Fisher Scientific (Fair Lawn, NJ) as analytical grade solvents.

75

Table 3-1: NCNPR Code, dosage form, serving size, type of tea, plant part of A.linearis
supplements

NCNPR Code
20750
19070
19069
19068

Dosage form
tea bag
tea bag
powder
powder

Serving size
N/A
1 tea bag
N/A
1 teaspoon

Red/Green
Red
N/A
N/A
Red

19067
19066
19065
19064
19063
19062
19061

tea bag
powder
Powder
powder
powder
powder
tea bag

N/A
N/A
1 teaspoon
N/A
2g
N/A
1 tea bag

green
Red
N/A
Red
N/A
N/A
N/A

19060
19059
19058
19057
19056
19055
19054
19053
19052
19051

tea bag
powder
tea bag
tea bag
powder
tea bag
tea bag
tea bag
powder
powder

N/A
1.5 teaspoon
N/A
N/A
N/A
1 tea bag (2 g)
N/A
N/A
N/A
N/A

Red
N/A
N/A
N/A
Red
N/A
N/A
Red
N/A
N/A

(N/A) indicates the lack of information.
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Additional notes
N/A
USDA organic
N/A
organic
Dolorado
Department
of
Agriculture
USDA organic
N/A
USDA organic
N/A
USDA organic
N/A
USDA
organic
contains other herbs
N/A
contains other herbs
USDA organic
contains other herbs
N/A
USDA organic
USDA organic
N/A
N/A
USDA
organiccontains other herbs

Plant part
leaves
N/A
N/A
N/A

N/A
N/A
N/A
leaves
leaves
N/A
leaves
N/A
N/A
N/A
N/A
N/A
leaves
leaves
N/A
leaves
N/A

3.2.2 Preparation of standard solutions:
Stock solutions containing the standard compounds were prepared separately at a concentration
of 2 mg/mL in methanol. Seven different concentration levels were prepared to obtain the
calibration curves, and each level was injected in triplicate. The range of the calibration curves
was 1-100 μg/mL for the compounds. However, additional concentration points (200-1000
μg/mL) were considered for compounds 4-6, 9 and 13 based on the pilot study using a
UHPLC‑PDA method.
3.2.3 Sample preparation:
Twenty-one products were purchased either as a powder or tea bags. For tea bags, three
representative sachets were randomly taken, emptied and mixed to represent the final product
and overcome sample non-homogeneity. Every product was ground to a fine powder using
Planetary Ball Mill PM 400 (Retsch). Two hundred milligrams of dried powdered plant samples
were weighed then sonicated in 2.0 mL of 80% methanol for 30 min followed by centrifugation
for 15 min. A volumetric flask of 10 mL was used to accommodate the supernatant. The
procedure was repeated four times with 2.0 mL 80% methanol, and the respective supernatants
were pooled. The volumetric flask was adjusted to reach 10 mL final volume with 80% methanol
then shaken exhaustively. An adequate volume of 2 mL was passed through a 0.45 μm
polytetrafluoroethylene membrane syringe filter into LC sample vial, and the remaining volume
was collected in 10 mL vial and stored in the refrigerator.
3.2.4 Validation procedure:
The UHPLC method was validated regarding linearity, precision, and accuracy according to
International Conference on Harmonization guidelines (ICH). The LOD and LOQ were
determined by injecting a series of dilute solutions with known concentrations for each standard.
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Signal-to-noise ratio equal to three and ten was defined for LOD and LOQ, respectively. The
method accuracy was determined in duplicate using a concentration of 100 μg/mL for two
samples. Three consecutive days (n = 3) serves as a test for intra and inter-day variation of the
assay.
3.2.5 Instrumentation and experimental conditions:
Acquity UPLC H-Class system (Waters Corporation) was used to perform the analyses including
the quaternary solvent manager, sampler manager-flow through needle, column heater, and PDA
detector connected to Waters Empower 3 data station. A Cortecs UPLC C18, 1.6 um, 2.1 x 100
mm also from Waters, was used. The temperature for the column and sample were maintained at
30°C and 10°C, respectively. The mobile phase, at a flow rate of 0.25 mL/min, included water
(A) and acetonitrile (B) boh containing 0.05% formic acid were applied in the following linear
gradient elution: 0 min, 90% A: 10% B in next 22 min to 75% A: 25% B in next 30 min.
Washing procedure for 2 min with 100% B was applied after separation followed by a reequilibration period for 7 min. Strong and weak needle wash solutions (95/5 and 10/90;
acetonitrile/water) were performed, respectively. The total run time for analysis was 30 min. The
injection volume was 2 μL, and the compounds were detected at 288 nm wavelength. Spiking the
samples with standard compounds then comparing the UV spectra and retention times were
necessary for identification. The mass spectrometric analysis was conducted with a QDa
equipped with an ESI source using the following parameters: Gain 2, probe temperature 600°C
and capillary voltage in positive and negative mode 3.0 kV. The positive and negative ion modes
in the range of m/z 100–900 was applied for samples analysis.
3.3

Results:

3.3.1 Isolation and structure elucidation:
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Phytochemical investigation of the MeOH extract of A. linearis mixed parts comprising leaves
and stems resulted in the isolation and characterization of one phenylpropanoid derivative,
syringin (1) along with 13 flavonoid glycosides including two flavanones, (S)-eriodictyol-6-C-D-glucopyranoside (2) and (R)-eriodictyol-6-C--D-glucopyranoside (3), four flavones,
isoorientin (4), orientin (5), vitexin (7), and isovitexin (10), two dihydrochalcones, aspalathin (6)
and nothofagin (13), four flavonol derivatives, bioquercetin (8), hyperoside (9), rutin (11),
isoquercitrin (12), and thermopsoside (14). Structure elucidation was mainly achieved by
spectroscopic data analysis including 1D and 2D NMR (1H, 13C, DEPTQ135, COSY, HSQC, and
HMBC), and confirmed by HR-ESI-MS data. Based on NMR data and the chromatograms, the
purity of phytoconstituents 1-14 was approximately 90-95%.
3.3.2 Sample Preparation:
The plant samples were composed of complex mixtures of components, and three extraction
techniques were employed. The authenticated plant sample (#16850) was extracted separately
with methanol, 80% methanol, and 70% methanol in water exhaustively to determine the optimal
extraction solvent. The abundance values for compounds 1-14 in the sample extracted with 80%
methanol was found to be higher than the samples extracted with pure methanol or 70%
methanol in water.
3.3.3 Method development and optimization:
Optimized chromatographic conditions were achieved after several trials with acetonitrile,
methanol, and water in different proportions for the mobile phase. A mobile phase containing
water and acetonitrile, both containing formic acid with a constant flow rate at 0.25 mL/min on
an Cortecs UPLC C18, 1.6 um, 2.1 x 100 mm using gradient elution at a fixed column
temperature of 30°C were deemed the optimal separation condition for the determination of
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compounds 1-14 in various samples. The different columns tried were Acquity UPLC BEH
Shield RP18, 1.8 um, 2.1 x 100 mm, and HSS T3, 2.1 x 100 mm. Each provided a different
combination of silanol activity, hydrophobicity, hydrolytic stability, and chemical interaction
with the analytes. Among these, the Cortecs UPLC C18 resolved peaks 1-14 adequately. Other
columns could not resolve the positional isomers 7-10, and diastereomers 8-11, and 9-12
satisfactorily under the same conditions.
3.3.4 Method Validation:
Quantitative determination of 14 compounds in various samples was achieved using the
UHPLC‑PDA method, and results were expressed as mg/100 mg on a dry weight basis. The
developed method was validated regarding sensitivity (limit of detection [LOD] and limit of
quantification [LOQ]), linearity, intra-day and inter-day precision for three consecutive days,
accuracy, specificity, stability, system suitability, and robustness. These validation parameters
enabled us to investigate the suitability of the method for routine analysis.
The seven-point calibration curve exhibited a linear correlation between concentration and peak
area as shown in Table 3-2. Calibration data indicated the linearity (r2 > 0.998) of the detector
response for compounds 1-14 from 1 to 100 μg/mL, with additional concentration points (2001000 μg/mL) were considered for compounds 4-6, 9 and 13. The limits of detection from 0.2-1
μg/mL was reported for the phenolic compounds (1-14) in this study. All samples and standard
were injected in triplicate.
Intra- and inter-day variation for this study was determined for the authenticated A. linearis plant
sample (#16850) and was lower than 5%. The analysis was conducted three times on three
different days, and each run was repeated in triplicate. The intra-day RSD for the replicates for
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compounds 1-14 were between 0.14 and 4.26% and RSD for the day-to-day replicates were
between 1.2 and 5.9%.
The method accurcy for the related compounds was assigned by spiking samples (#16850) with a
known amount for a mixture of compounds 1-14. This sample was extracted exhaustively four
times, dried and spiked with known amount of the standard compounds then extracted and
analyzed again under similar conditions. The evaluation for the accuracy of the method was
evaluated in duplicate at a concentration of 100 μg/mL. The percentage recovery of these
samples ranged from 90-110 %.
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Table 3-2: Calibration curves for compounds 1-14

1
2
3
4
5
6
7
8
9
10
11
12
13
14

Name
Syringin
Eriodictyol 1
Eriodictyol 2
Isoorientin
Orientin
Aspalathin
Vitexin
Bioquercetin
Hyperoside
Isovitexin
Rutin
Isoquercitrin
Nothofagin
Thermopsoside

Channel
280.0nm
280.0nm
280.0nm
280.0nm
280.0nm
280.0nm
280.0nm
280.0nm
280.0nm
280.0nm
280.0nm
280.0nm
280.0nm
280.0nm

R
0.999211
0.999198
0.999328
0.999653
0.998531
0.999529
0.998984
0.994722
0.997803
0.999337
0.998812
0.998852
0.999291
0.999190
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R^2
0.998424
0.998396
0.998656
0.999306
0.997064
0.999059
0.997969
0.989471
0.995611
0.998674
0.997625
0.997705
0.998583
0.998380

Equation
Y = 2.80e+003 X + 8.23e+002
Y = 1.76e+003 X + 7.03e+002
Y = 1.84e+003 X + 5.38e+002
Y = 2.52e+003 X - 1.64e+003
Y = 1.79e+003 X + 1.13e+002
Y = 4.62e+003 X - 2.30e+004
Y = 1.50e+003 X - 8.79e+002
Y = 1.63e+003 X + 6.59e+003
Y = 7.53e+002 X - 1.64e+003
Y = 3.97e+003 X - 1.12e+003
Y = 1.62e+003 X - 4.75e+002
Y = 1.19e+003 X - 1.52e+003
Y = 5.76e+003 X - 2.53e+003
Y = 3.45e+003 X + 3.83e+002

3.4

Discussion:

According to the WHO, the described risks associated with traditional medicines include direct
adverse events, side effects or unwanted treatment interactions, exposure of the individual to
misleading or unreliable information, and the use of poor quality, adulterated or counterfeit
products. Bearing in mind the claims of medical effectiveness and tremendous economic impact,
the possibility of herb-drug interactions, and the fermentation process which determines the
chemotaxonomic profile, there is a necessity to develop and validate analytical fingerprinting
approaches for identification and quantification of the phenolic compounds as markers for
rooibos tea samples. Although several analytical methods have been applied for the qualitative
and quantitative analysis of rooibos, the poor resolution, delay analysis time, and reduced
sensitivity and robustness hampered their suitability for routine applications.(Arries et al., 2017;
Bramati et al., 2002, 2003; Iswaldi et al., 2011; Elizabeth Joubert & de Beer, 2012; Schulz et al.,
2003; Stander et al., 2017) This highlights the necessity for robust research aimed at
standardizing rooibos herbal products and quality control particularly when dealing with
regioisomers or diastereomers which co-elute on a variety of stationary phases making the
separation complicated.
The main chemical classes reported are chalconoids, flavonoids, and phenylpropanoids alongside
with traces of lignans and phenolic acids. Unlike classical flavonoids (glycopyranosyloxy
flavonoids), glycopyranosyl flavonoid derivatives have superior characteristic features. For
instance, their glycone moiety is attached via the C-1” directly to the flavonoid backbone,
usually at the C-6 or C-8 position of the A ring as shown in aspalathin (6) (Figure 3-1). This
feature affords them the ability to resist the hydrolysis and be absorbed intact in the colon.
Therefore, C-glycosides have exclusive biological activities compared with their counterparts, O83

glycosides. During metabolism, they might react differently with the liver enzymes as well.(Zeng
et al., 2013)
Due to its ability to biosynthesize unique and rare secondary metabolites, rooibos tea is known
for its potent hypoglycemic and estrogenic activity.(Kawano et al., 2009; Krafczyk & Glomb,
2008; Muller et al., 2012; Shimamura et al., 2006) To the best of our knowledge, aspalathin
(acyclic dihydrochalcone) was isolated from Aspalathus linearis species as the sole natural
source. Additionally, nothofagin was found to be a rare compound derived from A. linearis, the
heartwood of Nothofagus fusca previously, and lately from the bark of a Chinese medicinal plant
Schoepfia chinensis.(E. Joubert et al., 2008) Yet, aspalathin and nothofagin recently were
detected in closely related and endangered species, Aspalathus pendula (the golden tea).(Johnson
et al., 2018; Stander et al., 2017) In addition to aspalathin and nothofagin, phytochemical
investigation of A. linearis species in this study afforded ten additional phenolic secondary
metabolites. The isolation of thermopsoside from A. linearis was reported for the first time.
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Figure 3-1: Chemical structures of isolated phytoconstituents 1-14 from Aspalathus linearis
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During the fermentation process (Figure 3-2), the triplet state of formyl group for the aspalathin
(dihydrochalcone glycoside) in the presence of heat and ultraviolet light permits proton
abstraction to give a phenoxy radical then O-quinone intermediate by generating hydrogen
peroxide. Subsequently, a quinone methide will form by O-quinone- quinone methide
tautomerism. One of the nucleophilic hydroxy groups in ring A will potentially attack the
Michael acceptor (1, 4 unsaturated carbonyl moiety) as an electrophilic center. Based on the re
and si face attack, this prochiral intermediate will result in either (S and R)-eriodictyol-6-C--Dglucopyranoside or (S and R)-eriodictyol-8-C--D-glucopyranoside with higher content for the
former isomers. However, an isomerization process via Wessely–Moser rearrangement could
increase the latter content based on the rate of formation. The oxidation process will convert
these intermediates subsequently to isoorientin and with further hydrolysis to orientin. These
final products might be responsible for the antioxidant activity reduction of fermented red
tea.(Marais et al., 2000)
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Figure 3-2: Proposed pathway for the formation of (S) and (R)-eriodictyol-6-C--Dglucopyranoside, (S) and (R)-eriodictyol-8-C--D-glucopyranoside, orientin and isorientin via
aspalathin during fermentation process
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The UHPLC‑UV separation of 80% methanol extracts of A. linearis is shown in Figure 3-3.
Optimization strategies were pursued by modifying the temperature, flow rate, mobile phase
gradient and stationary phase. Although higher temperature and increased flow rate reduced the
analysis time, they simultaneously affected the resolution. All 14 compounds were separated
within less than 30 min. The identification of the compounds in all samples was based on the
comparison of retention times and UV spectra with those of standards. The analysis was
performed on an authenticated plant material (#16850) and 21 dietary supplements. Figure 3-3
illustrates an example of the UHPLC‑UV at 288 nm. Of the 21 dietary supplement brands tested,
all products contained phenolic compounds with varied contents between the fermented and
unfermented rooibos tea products. The peaks of standard compounds in all samples were
identified by comparing the UV and MS spectra obtained with the standards (Figure 3-4), which
showed [M+ H]+ and [M+ Na]+ ions in the positive mode, and [M– H]− and [M– H+ HCO2H]−
ions in the negative mode (Table 3-3). The total content of phenolic compounds analyzed (1–14)
was found to be in the range from 1–3 % for fermented rooibos tea samples, and from 5–10 %
for unfermented rooibos tea samples (Figure 3-5).
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Figure 3-3: UHPLC‑UV Chromatograms of a standards mixture (1-14), authenticated plant
sample (#16850) and dietary supplements (#19053, #19059, #19062, and #19067) at 288 nm
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Figure 3-4: UV and mass spectra for compounds 1-14
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Figure 3-5: Quantitative analysis of flavonoids (2-14) in authenticated plant sample (#16850)
and dietary supplements (green tea #19067), and red tea (#19051, #19052, #19053, #19054,
#19055, #19056, #19057, #19058, #19059, #19060, #19061, #19062, #19063, #19064, #19065,
#19066, #19068, #19069, #19070, and #20750) at 288 nm. The results are arranged according to
the flavonoids subclasses; flavanone ((S)-eriodictyol-6-C--D-glucopyranoside (2) and (R)eriodictyol-6-C--D-glucopyranoside (3)), flavone (isoorientin (4), orientin (5), vitexin (7), and
isovitexin (10), dihydrochalcone (aspalathin (6) and nothofagin (13)), flavonol (bioquercetin (8),
hyperoside (9), rutin (11), isoquercitrin (12), and thermopsoside (14)).
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The characterization and confirmation of 14 compounds from plant samples and dietary
supplements claimed to contain A. linearis was achieved by liquid chromatography-mass
spectrometry with electrospray ionization (LC-ESI-MS) hyphenated technique coupled with
extractive ion monitoring. The method involved the use both positive and negative ion modes for
compounds 1–14. The standard compounds in the positive ion mode were observed at m/z 395.22
[M+ Na]+, 451.05 [M + H]+, 451.11 [M+ H]+, 449.18 [M+ H]+, 449.24 [M+ H]+, 452.92 [M+
H]+, 433.17 [M+ H]+, 611.20 [M + H]+, 465.19 [M + H]+, 433.17 [M+ H]+, 611.11 [M+ H]+,
465.31 [M+ H]+, 437.11 [M+ H]+, and 463.23 [M+ H]+, respectively. On the contrary, the
standard compounds in the negative ion mode were detected at m/z 417.27 [M– H+ HCO2H]−,
449.26 [M– H]−, 449.26 [M– H]−, 447.24 [M– H]−, 447.35 [M– H]−, 451.17 [M– H]−, 431.13
[M– H]−, 609.34 [M– H]−, 463.11 [M– H]−, 431.19 [M– H]−, 609.36 [M– H]−, 463.25 [M– H]−,
435.28 [M– H]−, and 461.28 [M– H]−, respectively. All compounds of interest displayed the
superior response in negative mode ionization. The chromatogram shows no overlapping peaks
at the retention time of interest. Also, the mass spectrum exhibited fragmentation behavior which
was diagnostic in the characterization of the compounds (Table 3-3). The most abundant
components detected were C-glycosides, and its neutral mass loss of hexose equals 120 Da
usually observed compared with the 162 Da with the O-counterparts which means the
fragmentation patterns could be useful for this type of compounds.
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Table 3-3: Compound name, retention time (min), LOD, LOQ, UV spectra, M.wt, molecular
formula, and MS of compounds used for analysis of A.linearis

Samp
le #

Compound
Name

tR
(min)

LOD
(μg/
mL)

LOQ
(μg/m
L)

M.w
t

1

Syringin

2.295

1

5

372.
37

Molecu
lar
formul
a
C17H24
O9

4.944

1

5

450.
12

6.187

1

5

1

5

1

5

1

5

1

5

1

5

1

5

1

5

1

5

1

5

2

3

(S)eriodictyol6-C--Dglucopyrano
side
(R)eriodictyol6-C--Dglucopyrano
side

10.24
8
11.10
6
13.98
0
17.16
4
17.76
8
18.70
1
19.63
0
21.15
6
21.91
6

UV (nm)

m/z
[M + H]+/ [M +
Na]+

m/z
[M – H]−/ [M –
H+ HCO2H]−

220,264,
383

395.22
Na]+

417.21[M – H+
HCO2H]−

C21H22
O11

215,288,
384

451.05(frag.,
433.17,415.29,3
31.01)

449.26(frag.,32
9.05)

450.
12

C21H22
O11

215,288,
384

451.11(frag.,
432.98,415.16,3
31.26)

449.26(frag.,32
9.07)

448.
10
448.
10
452.
13
432.
10
610.
15
464.
10
432.
10
610.
15
464.
10

C21H20
O11
C21H20
O11
C21H24
O11
C21H20
O10
C27H30
O16
C21H20
O12
C21H20
O10
C27H30
O16
C21H20
O12

211,269,
349
211,269,
349

4

Isoorientin

5

Orientin

6

Aspalathin

7

Vitexin

8

Bioquerceti
n

9

Hyperoside

10

Isovitexin

11

Rutin

12

Isoquercitri
n

13

Nothofagin

26.21
8

1

5

436.
14

C21H24
O10

226,287

14

Thermopsos
ide

28.33
8

1

5

462.
12

C22H22
O11

252,348
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227,288
214,268,
337
255,353
255,355
214,268,
337
255,353
255,350

[M

+

449.18(frag.,
329.13)
449.24(frag.,
329.47)
452.92(frag.,
434.98,333.32)
433.17(frag.,
415.29,313.01)
611.20(frag.,
465.05,303.12)
465.19(frag.,
303.04)
433.17(frag.,
415.10,312.87)
611.11(frag.,
465.25,303.11)
465.31(frag.,
303.11)
437.11(frag.,
419.29,
383.22,341.14,3
17.13)
463.23(frag.,
301.09)

447.24
447.35
451.17(frag.,33
0.94)
431.13
609.34
463.11
431.19
609.36
463.25
435.28(frag.,31
5.11)
461.28

The data suggest four compounds to be employed as quality markers for nutraceuticals claiming
to contain A. linearis; two dihydrochalcones, aspalathin and nothofagin alongside with two
flavanones,

(S)-eriodictyol-6-C--D-glucopyranoside

and

(R)-eriodictyol-6-C--D-

glucopyranoside. According to this study, the red type rooibos displayed the major compounds
as the flavones isoorientin and orientin followed by the flavanones, (S)-eriodictyol-6-C--Dglucopyranoside and (R)-eriodictyol-6-C--D-glucopyranoside. On the contrary, the aspalathin,
isoorientin, orientin, nothofagin followed by hyperoside and bioquercetrin found to be the major
compounds detected and quantified in for the unfermented rooibos tea (Figure 3-6).
Interestingly, the flavones such as orientin, isoorientin, vitexin, and isovitexin were suggested to
be the responsible compounds for the red color formation of red tea as mentioned in previous
studies as a consequence of the fermentation process for aspalathin and nothofagin, respectively.
However, their total concentrations relative to 100 mg of plant material was found to be similar
ranged from 0.75 to 1.62 mg, and 0.96 to 1.59 mg for the fermented and unfermented rooibos
tea, respectively. However, the percentage of the flavones to the total flavonoids detected in this
study was found to be higher for the fermented rooibos tea ranged from 48.21 to 50.06%
compared to the unfermented type from 16.18 to 20.96 % (Figure 3-6).

94

100%
90%
80%
70%
60%
Flavonol
50%

Dihydrochalcone

40%

Flavone

30%

Flavanone

20%
10%
20750
19070
19069
19068
19066
19065
19064
19063
19062
19061
19060
19059
19058
19057
19056
19055
19054
19053
19052
19051
19067
16850
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Figure 3-6: Percentage of flavonoid subclasses for compounds 2-14 to the total flavonoid
content in authenticated plant sample (#16850) and dietary supplements (green rooibos tea
#19067), and red rooibos tea (#19051, #19052, #19053, #19054, #19055, #19056, #19057,
#19058, #19059, #19060, #19061, #19062, #19063, #19064, #19065, #19066, #19068, #19069,
#19070, and #20750) at 288 nm.
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Table 3-4: Distribution and percentage of 14 phytochemicals in authenticated green plant
material (16850) and 21 herbal supplements claimed to contain A. linearis: syringin (1), (S)eriodictyol-6-C--D-glucopyranoside (2), (R)-eriodictyol-6-C--D-glucopyranoside (3),
isoorientin (4), orientin (5), aspalathin (6), vitexin (7), bioquercetin (8), hyperoside (9),
isovitexin (10), rutin (11), isoquercitrin (12), nothofagin (13) and thermopsoside (14).

Code #
16850
20750
19070
19069
19068
19067
19066
19065
19064
19063
19062
19061
19060
19059
19058
19057
19056
19055
19054
19053
19052
19051

1

2

3

4

0.05
0.02
0.03
0.02
0.01
0.09
0.01
0.02
0.03
0.02
0.02
0.03
0.02
0.02
0.02
0.05
0.01
0.01
0.01
0.02
0.01
0.03

0.04
0.36
0.44
0.40
0.32
0.08
0.26
0.39
0.38
0.34
0.38
0.21
0.42
0.31
0.17
0.21
0.34
0.36
0.35
0.42
0.37
0.33

0.07
0.36
0.43
0.38
0.31
0.11
0.27
0.39
0.37
0.33
0.38
0.27
0.41
0.30
0.21
0.21
0.33
0.35
0.34
0.41
0.37
0.36

0.42
0.67
0.69
0.56
0.52
0.74
0.63
0.58
0.61
0.59
0.58
0.34
0.70
0.47
0.30
0.39
0.49
0.58
0.47
0.70
0.58
0.52

Compounds. (mg/ 100 mg sample)
5
6
7
8
9
10
0.41
0.65
0.64
0.56
0.53
0.65
0.64
0.57
0.59
0.57
0.57
0.33
0.67
0.48
0.30
0.39
0.49
0.57
0.50
0.67
0.58
0.50

2.58
0.16
0.25
0.30
0.17
6.05
0.21
0.25
0.37
0.15
0.30
0.18
0.26
0.14
0.10
0.08
0.08
0.18
0.09
0.20
0.16
0.18

0.07
0.15
0.12
0.08
0.08
0.08
0.14
0.12
0.12
0.12
0.12
0.07
0.14
0.11
0.08
0.10
0.11
0.13
0.11
0.14
0.13
0.13
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0.16
0.20
0.16
0.16
0.23
0.45
0.19
0.17
0.14
0.13
0.18
0.10
0.18
0.13
0.07
0.09
0.05
0.10
0.02
0.18
0.10
0.15

0.21
0.22
0.23
0.35
0.24
0.47
0.25
0.23
0.21
0.20
0.27
0.13
0.24
0.30
0.12
0.15
0.13
0.20
0.11
0.27
0.19
0.19

0.06
0.10
0.11
0.10
0.08
0.12
0.10
0.09
0.09
0.09
0.09
0.07
0.11
0.08
0.06
0.06
0.07
0.09
0.07
0.11
0.09
0.10

11

12

13

14

0.08
0.04
0.06
0.03
0.03
0.18
0.02
0.05
0.05
0.02
0.05
0.03
0.05
0.03
0.01
0.02
0.01
0.01
0.01
0.04
0.02
0.04

0.14
0.08
0.12
0.08
0.06
0.34
0.08
0.07
0.09
0.07
0.09
0.04
0.09
0.11
0.05
0.05
0.03
0.05
0.03
0.09
0.06
0.10

0.30
0.03
0.04
0.03
0.02
0.52
0.03
0.04
0.05
0.02
0.05
0.02
0.04
0.02
0.01
0.01
0.02
0.03
0.02
0.03
0.02
0.03

0.04
0.03
0.02
0.02
0.02
0.05
0.03
0.01
0.03
0.02
0.02
0.01
0.02
0.50
0.02
0.02
0.02
0.02
0.01
0.02
0.02
0.02

The similarities in the percentage of flavones, orientin, isoorientin, vitexin, and isovitexin, for
both red and green teas are questionable. Although the orientin and isoorientin are suggested to
be the final products of the fermentation process of aspalathin, their contents were detected for
the green tea as similar to the red tea products. This observation suggests that orientin and
isoorientin might form via another biosynthetic route independent than aspalathin. Interestingly,
these two phytochemicals were specified in preceding studies to be the responsible ingredients
not only for the antioxidant activity reduction but also for the red color formation for the
fermented tea. However, the contents for these two phytoconstituents in this study were found to
be similar, and their contribution to the red color formation needs further research.
The variation between the herbal supplement labeled as green tea (#19067) and the authenticated
plant material (#16850) is acceptable. While the former contains entirely leaves as stated in the
label, the latter encompasses mixed parts of leave and stems which could be one of the aspects
that affected the content of the dihydrochalcone content in this study. The remarkable content for
thermopsoside in the herbal supplement #19057 compared with the other brands could be
attributed to other herbs listed in the product label.
In our recent in vitro safety assessment regarding the potential herb-drug interaction, these two
major and structurally related components, aspalathin and nothofagin, increased PXR activity to
1.56 and 1.38 fold, respectively. Moreover, further mRNA expression studies in HepG2 cells
displayed a remarkable increase in CYP3A4 gene expression after treatment with these
phytochemicals (30 µM). This observation should be taken into account when standardizing the
rooibos tea products indicating that green and red rooibos tea extract might interact differently
with CYP450 isozymes thanks to their distinctive chemical profiles and yields.
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In conclusions, the newly developed method is suitable for the quality control and chemical
fingerprint analysis of A. linearis plant samples and dietary supplements claimed to contain A.
linearis. UHPLC‑PDA‑MS method for the determination of phenolic compounds was found to
be efficient in providing low retention times and excellent resolution simultaneously. It is a
suitable method for identification and quantification of compounds in dietary supplements
claiming to contain A. linearis. It was validated for all the parameters tested, and 21 dietary
supplements were analyzed accordingly. All tested dietary supplements contained phenolic
compounds, and the quantities in these brands ranged from 1.50 to 9.85 mg/100 mg with higher
content observed for the unfermented products.
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4

CHAPTER 4:

ISOLATION, SYNTHESIS, AND DRUG INTERACTION POTENTIAL OF
SECONDARY METABOLITES DERIVED FROM THE MIRACLE TREE
(MORINGA OLEIFERA) LEAVES AGAINST CYP3A4 AND CYP2D6 ISOZYMES
Abstract:
Moringa oleifera Lam. is known as a drumstick tree that is widely cultivated in various
subtropical and tropical provinces. It has been called the miracle vegetable because all parts of
Moringa such as pods, leaves, roots, and seeds have been exploited to treat a variety of ailments.
Besides antioxidant properties, it shows antihypertensive, antimicrobial, antidiabetic, anticancer,
and

anti-inflammatory

activities

alongside

immunomodulatory,

cardioprotectant,

and

hepatoprotectant effects. Phytochemical investigation of M. oleifera (miracle tree) leaves
resulted in the isolation and characterization of one new compound, namely omoringone (1),
alongside fifteen known secondary metabolites (2-16) from several chemical classes including
flavonoids, terpenoids, lignans, and phenyl propanoids. Structure elucidation was achieved by
interpretation of the spectroscopic data (UV, IR, 1D, and 2D NMR experiments), confirmation
by HR-ESI-MS, and comparison of the measured values with the previously reported in the
literature. A plausible biosynthetic pathway for compound 1 was provided. Because of the low
isolation yields and limited supply, omoringone (1) and niazirin (14) were successively
synthesized. All the isolates were evaluated for their potential cytotoxicity against cancer and
normal cell lines (SK-MEL, KB, BT-549, SK-OV-3, Vero, LLC-PK1, and HepG2), and drug
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interaction potential against two principal CYP isozymes (CYP3A4 and CYP2D6). No
cytotoxicity effects were observed on any tested cell lines at 100 µM. The extract exhibited a
selective inhibitory effect on CYP3A4 isoform (IC50= 52.5 µg/mL). The inhibitory activity
against CYP3A4 was also observed with the compounds 1-4, 9-11, and 13 in an IC50 range from
41.5 to 100 µM with no remarkable effect on CYP2D6 isozyme
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4.1

Introduction:

Moringa oleifera is known as a drumstick tree that is widely cultivated in various subtropical and
tropical provinces. It belongs to the monogeneric genus Moringa within the Moringacea family.
Among 13 species, M. oleifera has so far become the most commonly used.(Saini et al., 2016)
Since 2001, the number of international congresses and scientific studies increased disseminating
information about the incredible properties of this species. Ayurvedic traditional medicine claims
that M. oleifera can prevent 300 diseases, and it has been called the miracle vegetable because all
parts of Moringa such as pods, leaves, roots, and seeds have been exploited to treat a variety of
ailments. Besides antioxidant properties, it shows antihypertensive, antimicrobial, antidiabetic,
anticancer, and anti-inflammatory activities alongside immunomodulatory, cardioprotectant, and
hepatoprotectant effects.(Leone et al., 2015; Stohs & Hartman, 2015)
Cytotoxicity screening and drug interaction potential of the phytochemicals derived from this
edible and widespread species need to be performed bearing in mind its popularity and
tremendous economic impact. Limited preceding studies displayed significant cytotoxicity
properties for the extracts of leaves and bark against breast and colorectal cancer cell lines.(AlAsmari et al., 2015; Jung, 2014; Stohs & Hartman, 2015) Cytotoxicity against HepG2 cells was
demonstrated only with the aqueous extract for M. oleifera leaves (IC50= 6 mg/mL). In the same
study, significant CYP3A4 inhibitory effects were observed, with IC50 values of 0.5 and 2.5
mg/mL for methanolic and aqueous extracts of the M. oleifera leaves respectively while less
inhibitory activities were reported for the root extracts (IC50> 10 mg/mL).(Monera et al., 2008)
Another study confirmed that the aqueous extract of M. oleifera powder leaves had shown a
potent inhibition on CYP3A4, in agreement with the previous finding.(Awortwe et al., 2014)
Both ethanol and aqueous leaf extracts were found to inhibit human CYP1A2, CYP2D6,
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CYP2E1, and CYP3A4 activities in vitro in a dose-dependent manner with the potent inhibition
exhibited against CYP1A2 isozyme (IC50=13.8 ± 9.8 μg/mL).(Taesotikul et al., 2010) The
fluorescence study revealed that both the extract and chlorogenic acid (IC50= 127.36 ± 2.98,
146.50 ± 3.46 µg/mL and 133.73 ± 1.79, 159.22 ± 3.53 µg/mL) had some inhibition with both
isozymes CYP3A4 and CYP2D6 but very less in comparison to their respective positive
inhibitors ketoconazole and quinidine.(Ahmmed et al., 2015) The potential of nine selected
widely used tropical medicinal herbs including M. olefiera in inhibiting human cytochrome P450
(CYP) isozymes was investigated in human liver microsomes by monitoring twelve probe
metabolites of nine probe substrates with UPLC/MS-MS, and M. oleifera leaves aqueous extract
showed weak inhibition of CYP1A2 and CYP2C9 with IC50 > 100 μg/ml.(Showande et al.,
2018) Owing to its immune booster effect, nutraceuticals claimed to contain M. olefiera are
administered concomitantly with anti-HIV medicines. Co‑administration of M. oleifera leaf
powder clinically at the traditional dose did not significantly alter the steady‑state
pharmacokinetics of nevirapine.(Monera-Penduka et al., 2017) However, M. oleifera leaf powder
altered the pharmacokinetics of antimalarial treatment, amodiaquine, in healthy human
volunteers showing a significant decrease in the Cmax after concurrent administration.(Olawoye
et al., 2018) Similarly, pharmacokinetic studies conducted in Swiss albino mice indicated that M.
oleifera increased the plasma concentration of rifampicin when administered concurrently.(Pal et
al., 2011)
However, most of these studies conducted a simple biological activity and were limited to the
solvent extracts but not performed on the chemical constituents. Notably, further studies are vital
to determine the phytochemical components of M. oleifera responsible for the metabolic
interaction. Therefore, the current study aims to isolate the secondary metabolites from M.
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olefiera, and investigate the inhibitory effects of the extract and isolates in recombinant CYPs
system for in vitro HDI studies on two principal isozymes (CYP3A4 and CYP2D6) along with
its potential cytotoxicity effects.
4.2

Materials and methods:

4.2.1 General experimental procedures:
The NMR spectra were obtained on Bruker Avance DRX spectrometer at 400 MHz for 1H
experiments and 100 MHz for 13C experiments. Using standard pulse instrument software, other
2D experiments (DEPTQ135, COSY, HSQC, HMBC, and NOESY) were recorded. DMSO or
CD3OD solvents were used as the internal standards and residual solvents to obtain and calibrate
the spectrum, respectively. High-resolution electrospray ionization mass spectra (HR-ESI-MS)
were acquired by injection the samples directly to an Agilent Technologies 6200 series mass
spectrometer in the positive and negative ion modes. Chiroptical techniques were employed to
assign the absolute configuration using an Olis DSM 20 circular dichroism spectrophotometer
(Olis, Inc.) and confirmed by AUTOPOL IV Automatic Polarimeter (Rudolph, Hackettstown,
NJ, USA) to measure the specific rotation. Agilent Technologies Cary 630 FTIR.IR was
performed to record the IR spectra. The isolation and fractionation procedures were performed
on column chromatography subjected on silica gel (32-63μ, Dynamic adsorbents Inc.), Sephadex
LH20 (Sigma-Aldrich), or reversed-phase C-18 (Polar bond, J. T. Baker) while the analytical
TLC was carried out on silica gel F254 aluminum sheet (20 × 20 cm, Fluka) or Silica 60 RP-18
F254S aluminum sheet (20 × 20 cm, Merck). Savant Speed Vac Plus SC210A Concentrator was
employed to concentrate and dry the samples. After isolation, visualization of the spots was
observed under UV light at 254 or 365 nm followed by spraying with 1% vanillin dissolved in
10% H2SO4/ethanol reagent and heating via heat gun for the detection of phenolic compounds.
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All materials, reagents and solvents used in the isolation, fractionation, synthesis and purification
steps were purchased from Fisher Scientific (Fair Lawn, NJ).
4.2.2 Plant material:
The dried leaves of M. oleifera were obtained from Dr. Bello M. Oluwasesan, Nigeria in August
2016. According to National Center for Natural Products Research (NCNPR) guidelines for
processing and packaging, the specimen (NCNPR # 18332) was prepared and deposited by Dr.
Vijayasankar Raman in the herbarium of NCNPR, School of Pharmacy, University of
Mississippi. The morphological and chemical properties were compared with the reference
sample (NCNPR #11695) at the NCNPR as process for the authentication.
4.2.3 Extraction and isolation of compounds:
The dried leaves of M. oleifera species (671 g) were ground to a fine powder and extracted
successively using continuous extraction method by percolation process with hexane (4 liters × 5
times), acetone (4 liters × 5 times), and methanol (4 liters × 5 times) respectively at room
temperature. The methanol solution was then evaporated under reduced pressure at 40 °C to
yield a dried methanolic crude extract (73 g). An aliquot of the methanol soluble portion was
fractionated by VLC over reversed phase C-18 column chromatography (25 cm × 10 cm) using
water/methanol gradient to provide eleven parent fractions (1-11). Fr. 4 (3.4 g) was fractionated
by CC over sephadex LH-20 (78 cm × 5.5 cm) with methanol and subsequently subjected on
repeated cc [silica gel (93 cm × 3 cm), ethyl acetate/chloroform/methanol/water (15:8:4:1,
6:4:4:1); silica gel (94 cm × 2.5 cm), ethyl acetate/chloroform/methanol/water (15:8:4:1,
6:4:4:1); and silica gel (99 cm × 2.5 cm), ethyl acetate/chloroform/methanol/water (10:6:4:1)]
then purified by preparative TLC to yield astragalin (4, 5.1 mg), 2,6-dimethyl-7-octene-2,3,6triol (5, 1.5 mg), euodionoside B (8, 14.7 mg), isolariciresinol-3a-O--D-glucopyranoside (11, 5
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mg), 2-hexenyl β-D-glucopyranoside (12, 40 mg), niazirin (14, 5.6 mg), benzyl -primeveroside
(15, 41.8 mg) and methyl 4-(-L-rhamnopyranosyloxy)benzylcarbamate (16, 4.7 mg). Fr. 5 (4.1
g) was subjected to CC on Sephadex LH-20 (78 cm × 5.5 cm) with methanol followed by
repeated CC [silica gel (89.5 cm × 4 cm), chloroform/methanol (9:1, 8.5:1.5, and 8:2); silica gel
(90 cm × 2.75 cm), chloroform/methanol (9:1, 8:2); and silica gel (75 cm × 2 cm), ethyl
acetate/chloroform/methanol/water (15:8:4:1)] to afford omoringone (1, 1.5 mg), rutin (2, 117
mg), isoquercitrin (3, 792 mg), lariciresinol 9-O--D-glucopyranoside (9, 28.9 mg), and (+)pinoresinol-4-O--D-glucopyranoside (10, 10.3 mg). Fr. 7 (1.5 g) was applied to CC over
Sephadex LH-20 (78 cm × 5.5 cm) with methanol and subsequently subjected on normal phase
silica gel (92 cm × 3.25 cm) and eluted with ethyl acetate/chloroform/methanol/water gradient
systems (15:8:4:1) to produce (S) linalyl -D-glucopyranoside (6, 5.3 mg), (S) linalyl primeveroside (7, 24.2 mg) and octadecadienoic acid (13, 28.9 mg). Structure elucidation of the
isolated compounds was performed by analysis of their spectroscopic data including 1D and 2D
NMR, IR, and spectrometric analysis by HR-ESI-MS.
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4.2.3.1 Omoringone (1):
UV (MeOH) λmax: 313.2, 229.6 nm (Figure 4-1);

13

C NMR (101 MHz, CH3OH-d4) δ 201.33,

159.83, 145.36, 131.20, 129.80, 126.27, 117.83, 99.64, 73.72, 72.17, 71.89, 70.86, 49.64, 49.43,
49.21, 49.00, 48.79, 48.57, 48.36, 27.22, 18.02 (Figure 4-2); 1H NMR (CH3OH-d4, 400 MHz):
(Figure 4-3); HR-ESI-MS (positive ion mode) m/z: 309.1329 [M+H]+, calculated 309.1338 for
C16H21O6 (Figure 4-4).

10.085 Peak 1

313.2
AU

0.10

229.6

0.05

250.00

300.00
nm

350.00

400.00

10.085

0.00
200.00

AU

0.10

0.05

0.00
0.00

2.00

4.00

6.00

8.00
Minutes

10.00

12.00

14.00

Figure 4-1: UV spectrum and chromatogram of 1, (313 nm: purity 94.55%)
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Figure 4-2: 13C NMR spectrum of 1 in CD3OD

Figure 4-3: 1H NMR spectrum of 1 in CD3OD
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Figure 4-4: HR-ESI-MS of 1
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4.2.3.2 Rutin (2):
UV (MeOH) λmax: 354.1, 255.3, 202.9 nm (Figure 4-5);

13

C NMR (101 MHz, DMSO-d6) δ

177.79, 164.62, 161.65, 157.04, 156.87, 148.87, 145.20, 133.73, 122.04, 121.60, 116.71, 115.68,
104.37, 101.63, 101.20, 99.16, 94.05, 76.88, 76.34, 74.52, 72.28, 71.00, 70.82, 70.44, 68.70,
67.45, 18.20 (Figure 4-6). 1H NMR (DMSO-d6, 400 MHz): (Figure 4-7); HR-ESI-MS (negative
ion mode) m/z: 609.1464 [M-H]-, calculated 609.1456 for C27H29O16 (Figure 4-8).
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Figure 4-5: UV spectrum and chromatogram of 2, (350 nm: purity 94.49%)
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Figure 4-6: 13C NMR spectrum of 2 in DMSO

Figure 4-7: 1H NMR spectrum of 2 in DMSO
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Figure 4-8: HR-ESI-MS of 2
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4.2.3.3 Isoquercitrin (3):
UV (MeOH) λmax: 353.5, 255.3, 203.5 nm (Figure 4-9);

13

C NMR (101 MHz, DMSO-d6) δ

177.53, 164.21, 161.32, 156.41, 156.26, 148.54, 144.89, 133.38, 121.69, 121.25, 116.29, 115.30,
104.06, 100.92, 98.75, 93.60, 77.64, 76.57, 74.17, 70.00, 61.04 (Figure 4-10); 1H NMR (DMSOd6, 400 MHz): (Figure 4-11); HR-ESI-MS (negative ion mode) m/z: 463.0885 [M-H]-, calculated
463.0877 for C21H19O12 (Figure 4-12)
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Figure 4-9: UV spectrum and chromatogram of 3, (350 nm: purity 98.28%)
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Figure 4-10: 13C NMR spectrum of 3 in DMSO

Figure 4-11: 1H NMR spectrum of 3 in DMSO
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Figure 4-12: HR-ESI-MS of 3
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4.2.3.4 Astragalin (4):
UV (MeOH) λmax: 346.7, 265.1 nm (Figure 4-13); 13C NMR (126 MHz, CH3OH-d4) δ 178.11,
164.65, 160.19, 157.82, 157.08, 157.04, 134.09, 130.90, 121.31, 114.71, 104.30, 102.76, 98.57,
93.42, 76.96, 76.56, 74.24, 69.89, 61.12 (Figure 4-14); 1H NMR (CH3OH-d4, 500 MHz):
(Figure 4-15); HR-ESI-MS (negative ion mode) m/z: 447.0913 [M-H]-, calculated 447.0928 for
C21H19O11 (Figure 4-16).
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Figure 4-13: UV spectrum and chromatogram of 4, (350 nm: purity 94.72%)
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Figure 4-14: 13C NMR spectrum of 4 in CD3OD

Figure 4-15: 1H NMR spectrum of 4 in CD3OD
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Figure 4-16: HR-ESI-MS of 4
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4.2.3.5 2,6-Dimethyl-7-octene-2,3,6-triol (5):
13

C NMR (101 MHz, CH3OH-d4) δ 146.79, 112.19, 80.42, 74.11, 74.05, 49.84, 49.63, 49.41,

49.20, 48.99, 48.77, 48.56, 40.95, 27.89, 26.91, 25.72, 25.28 (Figure 4-17); 1H NMR (CH3OHd4, 400 MHz): (Figure 4-18); HR-ESI-MS (negative ion mode) m/z: 223.0370 [M+Cl]+,
223.1101 calculated for C10H20O3Cl (Figure 4-19)

Figure 4-17: 13C NMR spectrum of 5 in CD3OD
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Figure 4-18: 1H NMR spectrum of 5 in CD3OD

Figure 4-19: HR-ESI-MS of 5
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4.2.3.6 (S) Linalyl--D-glucoside (6):
13

C NMR (126 MHz, CH3OH-d4) δ 143.06, 130.76, 124.27, 114.42, 98.13, 80.06, 76.83, 76.19,

73.78, 70.32, 61.40, 41.24, 24.46, 22.26, 21.76, 16.32 (Figure 4-20); 1H NMR (CH3OH-d4, 500
MHz): (Figure 4-21); HR-ESI-MS (positive ion mode) m/z: 335.1728 [M+H+H2O]+, calculated
335.2070 for C16H31O7 (Figure 4-22).

Figure 4-20: 13C NMR spectrum of 6 in CD3OD
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Figure 4-21: 1H NMR spectrum of 6 in CD3OD

Figure 4-22: HR-ESI-MS of 6
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4.2.3.7
13

(S)-Linalyl--primeveroside (7):

C NMR (101 MHz, CH3OH-d4) δ 142.91, 130.77, 124.28, 114.61, 103.96, 98.14, 80.22, 76.63,

76.13, 75.06, 73.73, 73.40, 70.04, 69.76, 68.36, 65.41, 41.27, 24.53, 22.29, 21.88, 16.40
(Figure 4-23); 1H NMR (400 MHz, CH3OH-d4): (Figure 4-24); HR-ESI-MS (positive ion mode)
m/z: 487.2148 [M+K]+, calculated 487.1945 for C21H36O10K (Figure 4-25).

Figure 4-23: 13C NMR spectrum of 7 in CD3OD
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Figure 4-24: 1H NMR spectrum of 7 in CD3OD

Figure 4-25: HR-ESI-MS of 7
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4.2.3.8 Euodionoside B (8):
13

C NMR (101 MHz, CH3OH-d4) δ 137.66, 124.41, 101.44, 76.70, 76.41, 73.72, 71.58, 70.19,

70.03, 67.28, 66.39, 61.27, 44.31, 37.07, 34.49, 28.38, 23.81, 22.41, 18.86 (Figure 4-26); 1H
NMR (400 MHz, CH3OH-d4): (Figure 4-27); HR-ESI-MS (negative ion mode) m/z: 423.1776
[M+Cl]-, calculated 423.1786 for C19H32O8Cl (Figure 4-28).

Figure 4-26: 13C NMR spectrum of 8 in CD3OD
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Figure 4-27: 1H NMR spectrum of 8 in CD3OD

Figure 4-28: HR-ESI-MS of 8
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4.2.3.9 Lariciresinol 9-O--D-glucopyranoside (9):
UV (MeOH) λmax: 279.9, 227.2, 200.4 nm (Figure 4-29);

13

C NMR (101 MHz, CH3OH-d4) δ

147.60, 145.73, 144.42, 134.17, 132.28, 120.89, 118.45, 114.81, 114.65, 112.17, 109.47, 103.36,
82.83, 76.75, 76.59, 73.82, 72.22, 70.28, 67.17, 61.37, 55.11, 50.31, 42.53, 32.51 (Figure 4-30);
1

H NMR (400 MHz, CH3OH-d4): (Figure 4-31); HR-ESI-MS (negative ion mode) m/z: 557.1798

[M+H]+, calculated 557.1790 for C26H34O11Cl (Figure 4-32).
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Figure 4-29: UV spectrum and chromatogram of 9, (280 nm: purity 99.19%)
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Figure 4-30: 13C NMR spectrum of 9 in CD3OD

Figure 4-31: 1H NMR spectrum of 9 in CD3OD
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Figure 4-32: HR-ESI-MS of 9
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4.2.3.10 (+)-Pinoresinol-4-O--D-glucopyranoside (10):
UV (MeOH) λmax: 278.0, 227.8, 201.0 nm (Figure 4-33);

13

C NMR (126 MHz, DMSO-d6) δ

150.76, 149.37, 147.79, 147.68, 137.03, 133.99, 120.49, 119.97, 117.00, 116.99, 112.37, 112.24,
101.97, 87.03, 86.72, 78.87, 78.70, 75.06, 72.86, 72.79, 71.50, 62.49, 57.53, 57.44, 55.57, 55.41
(Figure 4-34);1H NMR (500 MHz, DMSO-d6): (Figure 4-35); HR-ESI-MS (negative ion mode)
m/z: 555.1643 [M+Cl]+, calculated 555.1634 for C26H32O11Cl (Figure 4-36).
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Figure 4-33: UV spectrum and chromatogram of 10, (278 nm: purity 90.42%)
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Figure 4-34: 13C NMR spectrum of 10 in DMSO

Figure 4-35: 1H NMR spectrum of 10 in DMSO
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Figure 4-36: HR-ESI-MS of 10
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4.2.3.11 Isolariciresinol-3a-O--D-glucopyranoside (11):
UV (MeOH) λmax: 283.6, 201.0 nm (Figure 4-37); 13C NMR (126 MHz, CH3OH-d4) δ 168.16,
148.91, 147.14, 145.81, 145.12, 138.65, 134.36, 129.16, 123.13, 117.38, 116.09, 114.33, 112.43,
105.16, 78.29, 78.10, 77.84, 75.18, 71.65, 69.57, 65.21, 62.74, 56.50, 56.42, 56.26, 47.88, 45.90,
39.54, 33.84 (Figure 4-38);1H NMR (500 MHz, CH3OH-d4): (Figure 4-39); HR-ESI-MS
(negative ion mode) m/z: 567.2081 [M+CO2H]-, calculated 567.2078 for C27H35O13
(Figure 4-40).
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Figure 4-37: UV spectrum and chromatogram of 11, (283 nm: purity 90.66%)
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Figure 4-38: 13C NMR spectrum of 11 in CD3OD

Figure 4-39: 1H NMR spectrum of 11 in CD3OD
133

Figure 4-40: HR-ESI-MS of 11
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4.2.3.12 2-hexenyl-β-D-glucopyranoside (12):
13

C NMR (101 MHz, CH3OH-d4) δ 136.03, 130.07, 129.44, 127.32, 102.99, 78.10, 77.87, 75.06,

71.65, 71.00, 62.78, 35.48, 23.36, 14.16 (Figure 4-41); 1H NMR (400 MHz, CH3OH-d4):
(Figure 4-42); HR-ESI-MS (negative ion mode) m/z: 297.1113 [M+Cl]-, calculated 297.1105 for
C12H22O6Cl (Figure 4-43).

Figure 4-41: 13C NMR spectrum of 12 in CD3OD
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Figure 4-42: 1H NMR spectrum of 12 in CD3OD

Figure 4-43: HR-ESI-MS of 12
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4.2.3.13 Octadecadienoic acid (13):
13

C NMR (126 MHz, CH3OH-d4) δ 135.15, 133.00, 129.72, 124.96, 74.48, 74.34, 71.63, 36.93,

29.18, 29.01, 28.83, 25.11, 24.79, 20.30, 13.27 (Figure 4-44); 1H NMR (500 MHz, CH3OH-d4):
(Figure 4-45); HR-ESI-MS (negative ion mode) m/z: 327.2180 [M-H]-, calculated 327.2172 for
C18H31O5 (Figure 4-46).

Figure 4-44: 13C NMR spectrum of 13 in CD3OD
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Figure 4-45: 1H NMR spectrum of 13 in CD3OD

Figure 4-46: HR-ESI-MS of 13
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4.2.3.14 Niazirin (14):
UV (MeOH) λmax: 271.3, 220.5 nm (Figure 4-47); 13C NMR (126 MHz, CH3OH-d4) δ 157.08,
130.20, 125.51, 119.90, 117.94, 99.50, 73.59, 72.03, 71.75, 70.51, 49.51, 49.34, 49.17, 49.00,
48.83, 48.66, 48.49, 22.72, 17.97 (Figure 4-48);

1

H NMR (500 MHz, CH3OH-d4):

(Figure 4-49); HR-ESI-MS (negative ion mode) m/z: 324.1089 [M+HCO2]-, calculated 324.1084
for C15H18NO7 (Figure 4-50).
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Figure 4-47: UV spectrum and chromatogram of 14, (272 nm: purity 90.42%)
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Figure 4-48: 13C NMR spectrum of 14 in CD3OD

Figure 4-49: 1H NMR spectrum of 14 in CD3OD
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Figure 4-50: HR-ESI-MS of 14
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4.2.3.15 Benzyl--primeveroside (15):
13

C NMR (101 MHz, CH3OH-d4) δ 138.98, 129.41, 129.35, 128.85, 105.52, 103.35, 77.92,

77.69, 76.98, 75.07, 74.87, 72.07, 71.54, 71.18, 69.88, 66.91 (Figure 4-51); 1H NMR (400 MHz,
CH3OH-d4): (Figure 4-52); HR-ESI-MS (negative ion mode) m/z: 437.1225 [M+Cl]-, calculated
437.1215 for C18H26O10Cl (Figure 4-53).

Figure 4-51: 13C NMR spectrum of 15 in CD3OD
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Figure 4-52: 1H NMR spectrum of 15 in CD3OD

Figure 4-53: HR-ESI-MS of 15
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4.2.3.16 Methyl 4-(-l-rhamnopyranosyloxy)benzylcarbamate (16):
UV (MeOH) λmax: 395.2, 271.3, 220.5 nm (Figure 4-54); 13C NMR (101 MHz, CH3OH-d4) δ
155.56, 132.98, 128.21, 116.12, 98.48, 72.44, 70.83, 70.67, 69.18, 51.14, 43.54, 16.61
(Figure 4-55); 1H NMR (400 MHz, CH3OH-d4): (Figure 4-56); HR-ESI-MS (negative ion
mode) m/z: 362.1014 [M+Cl]-, calculated 362.1007 for C15H21NO7Cl (Figure 4-57).
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Figure 4-54: UV spectrum and chromatogram of 16, (221 nm: purity 85.56%)

144

Figure 4-55: 13C NMR spectrum of 16 in CD3OD

Figure 4-56: 1H NMR spectrum of 16 in CD3OD
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Figure 4-57: HR-ESI-MS of 16
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4.2.4 Chemical synthesis of intermediates and compounds:
4.2.4.1 1,2,3,4-tetra-O-acetate-L-rhamnopyranoside (18):
L-rhamnose monohydrate (17) (2.5 g, 15.23 mmol) and a catalytic amount of DMAP (4-dimethyl
aminopyridine) (186 mg, 1.52mmol) were dissolved in anhydrous pyridine (8.9 ml). Then, acetic
anhydride (10.4 ml) was added to the solution and stirred for 16 h at room temperature under N2
atmosphere. After completion of the reaction, the crude mixture was concentrated and the excess
pyridine was co-evaporated with toluene. The mixture was dissolved in EtOAc, and washed with
1.0 N HCl, NaHCO3, and brine (aqueous 5% NaCl), respectively. The organic layer was dried
over anhydrous Mg2SO4, and co-evaporated with toluene (2 times).
4.2.4.2 2,3,4-tri-O-acetate-L-rhamnopyranose hemiacetal (19):
Hydrazine acetate (0.27 g, 3.01 mmol) was added to a solution of 1,2,3,4-tetra-O-acetate-Lrhamnopyranoside (18) (1 g, 3.01mmol) in DMF (13 mL) at 50°C and stirred the reaction for 2 h
under N2. When the product forms and the starting material disappears, the mixture was diluted
with EtOAc, washed with brine. The crude product was dried over anhydrous Mg2SO4 and
concentrated to give the yellow oily product.
4.2.4.3 2,3,4-tri-O-acetate-α-L-rhamnosyl trichloro acetimidate (20):
2,3,4-tri-O-acetate-L-rhamnopyranose hemiacetal (19) (0.87 g, 3 mmol) was treated with
trichloroacetonitrile (2.71 mL, 27 mmol) and DBU (0.16 g, 1.05 mmol) in anhydrous DCM (10
mL). The mixture was stirred for 2 h at RT and concentrated later under rotavap.
4.2.4.4 Synthesis of omoringone (1):
2,3,4-tri-O-acetate-α-L-rhamnosyl trichloro acetimidate (20) (0.325 g, 0.75 mmol) and 4hydroxy benzylidene acetone (21) (0.14 g, 0.90 mmol) with molecular sieves (3 Å) were taken in
freshly distilled DCM (10 mL) at 0°C and stirred for 30 min under N2 atmosphere. To this
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reaction mixture, TMSOTf (135.11 μL, 0.75 mol) was added dropwise at 0°C and slowly
allowed the reaction mixture to RT and stirred overnight. After completion of all the starting
materials based on TLC, the reaction mixture was filtered and dissolved in CHCl 3 (30 mL). The
organic layer was extracted with aq. NaHCO3 solution, dried over anhydrous Mg2SO4 and
concentrated under rotavap and reduced pressure to provide 4-[(2,3,4-tri-O-acetyl-α-L- rhamno
pyranosyl)oxy]- benzylidene acetone (22). This crude mixture containing the latter was dissolved
in anhydrous methanol that contained a catalytic amount of sodium methoxide (350 μL). The
reaction mixture was allowed to stir at ambient temperature for 30 min under N2. After total
consumption of starting material, the reaction mixture was neutralized by the addition of
Amberlite IR-120 (H+) resin. Then, the reaction mixture was filtered and concentrated under
reduced pressure to obtain a crude product containing omoringone (1). The crude product was
purified by silica gel chromatography using a gradient of chloroform: methanol (9: 1, v/v) to
obtain omoringone (1) as semisolid (12 mg, 62%).
4.2.4.5 Synthesis of niazirin (14):
2,3,4-tri-O-acetate-α-L-rhamnosyl trichloro acetimidate (20) (0.325 g, 0.75 mmol) and 4hydroxy benzene acetonitrile (23) (0.12 g, 0.90 mmol) with molecular sieves (3 Å) were taken in
freshly distilled DCM (10 mL) at 0°C and stirred for 30 min under N2 atmosphere. To this
reaction mixture, TMSOTf (135.11 μL, 0.75 mol) was added dropwise at 0°C and slowly
allowed the reaction mixture to RT and stirred for overnight. After completion of all the starting
materials based on TLC, the reaction mixture was filtered and dissolved in CHCl 3 (30 mL). The
organic layer was extracted with aq. NaHCO3 solution, dried over anhydrous Mg2SO4 and
concentrated under rotavap and reduced pressure to provide 4-[(2,3,4-tri-O-acetyl-α-L- rhamno
pyranosyl)oxy]-benzeneacetonitrile (24). This mixture containing compound 22 was dissolved in
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anhydrous methanol containing a catalytic amount of sodium methoxide (200 μL). The reaction
mixture was allowed to stir at ambient temperature for 30 min under N2. After total consumption
of starting material, the reaction mixture was neutralized by the addition of Amberlite IR-120
(H+) resin to neutralize the mixture. Then, the reaction mixture was filtered and concentrated
under reduced pressure to obtain a crude product containing niazirin (14). The crude product was
purified by silica gel chromatography using a gradient of chloroform: methanol (9: 1, v/v) to
obtain niazirin (14) as semisolid (62 mg, 62%).
4.2.5 Cytotoxicity assay:
The isolated phytochemicals were evaluated for their cytotoxicity potential in a cell growth
inhibition assay established at the National Center for Natural Products Research.(Zhang et al.,
2016) Four human solid tumor cell lines (melanoma: SK-MEL, epidermal carcinoma: KB, breast
ductal carcinoma: BT-549, and ovarian carcinoma: SK-OV-3), and three liver and kidney cell
lines (African green monkey kidney fibroblast: Vero, pig kidney epithelial: LLC-PK1 and human
liver cells: HepG2) were used in the presence of DMSO and doxorubicin as the negative and
positive controls, respectively. The assay was performed in 96-well tissue culture-treated
microplates. Cells were seeded to the wells of the plate (25,000 cells/well) and incubated for 24 h
before treating with the test samples for 48 h. Cell viability was determined using the supravital
dye Neutral Red according to the procedure described earlier.(Borenfreund & Puerner, 1985;
Ravu et al., 2015) IC50 values were calculated from concentration-response curves of %
inhibition of cell viability versus test concentrations.
4.2.6 Inhibitory activity with recombinant CYP assay:
The assay to determine the inhibitory activity of test samples on the metabolic activity of CYPs
was performed under similar conditions as earlier reported.(Manda, Dale, et al., 2014) The
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methanol extract of M. oleifera and its constituents along with positive controls were serially
diluted in a solution (100 µL) of cofactors mix, CYP proteins (0.05 mg of protein/mL), and G-6PDH to achieve six concentrations ranging from 0.1 to 100 µg/mL for the extract and 0.1 to 100
µM for the pure compounds. DMSO was used as the vehicle control. Initial readings were
recorded to report the inherent fluorescence then the plates were incubated at 37 °C for 10 min.
Initiation the enzymatic reaction was achieved by the addition of the enzyme substrate mixture
(100 µL) followed by incubation for 45 min (according to instructions provided for each
enzyme). The incubation mixture with a total volume of 200 µL was transferred to a 96-well
microplate. Termination of the enzymatic reaction was performed by the addition of 75 µL of ice
cold acetonitrile/0.5M Tris base (80:20). For each substrate, fluorescence was measured on a
Spectramax M5 plate reader (Molecular Devices, Sunnyvale, CA, USA) at specified excitation
and emission wavelengths. IC50 values were calculated by profiling the tested concentrations
against observed enzyme inhibition (%).
4.3

Results:

4.3.1 Isolation and Structure elucidation:
All isolated secondary metabolites were obtained from the methanol soluble portion of M.
oleifera leaves by repeated column chromatographic techniques (silica gel, RP-18 silica gel, and
Sephadex LH-20) as well as preparative TLC over silica gel. Phytochemical investigation of
MeOH extract for M. oleifera leaves resulted in the isolation and characterization of one new
benzyl acetone rhamnoside, namely omoringone (1), together with 15 known secondary
metabolites (2-16). Based on the extensive spectroscopic (1D and 2D NMR) and spectrometric
(HR-ESI-MS) analysis, known compounds were identified as rutin (2), isoquercitrin (3),
astragalin (4), 2,6-dimethyl-7-octene-2,3,6-triol (5), (S) linalyl -D-glucoside (6), (S) linalyl -
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primeveroside (7), euodionoside B (8), lariciresinol 9-O--D-glucopyranoside (9), (+)pinoresinol-4-O--D-glucopyranoside (10), isolariciresinol-3a-O--D-glucopyranoside (11), 2Hexenyl β-D-glucopyranoside (12), octadecadienoic acid (13), niazirin (14), benzyl primeveroside (15), methyl 4-(-L-rhamnopyranosyloxy)benzylcarbamate (16) (Figure 4-58).
The NMR data (1H, 13C, DEPT135) for compound 1 and 14 have been shown in Table 4-1, and
Table 4-2, respectively.

151

Figure 4-58: Chemical structures of isolated phytoconstituents 1-16 from Moringa olefiera
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Table 4-1: 1H (400 MHz) and 13C (100 MHz) NMR spectroscopic data of compound 1 (in
MeOD, δ in ppm, J in Hz).
Position
1
2
3
4
1’
2’, 6’
3’, 5’
4’
1”
2”

Multiplicity
CH3
C=O
CH
CH
C
CH
CH
C
CH
CH

3”

CH

4”
5”
6”

CH
CH
CH3

1

H (δ)
2.38 (3H, s)

13

C (δ)
27.22
201.33
6.71 (1H, d, J=16.3 Hz)
126.27
7.64 (1H, d, J=16.3 Hz)
145.36
129.80
7.61 (2H, d, J=8.7 Hz)
131.20
7.14 (2H, d, J=8.7 Hz)
117.83
159.83
5.52 (1H, d, J=1.7 Hz)
99.64
4.03 (1H, dd, J=3.4, 1.8 71.89
Hz)
3.86 (1H, dd, J=9.4, 3.5 72.17
Hz)
3.49 (1H, t, J=9.4 Hz)
73.72
3.65 – 3.57 (1H, m)
70.86
1.24 (3H, d, J=6.1 Hz)
18.02

Table 4-2: 1H (400 MHz) and 13C (100 MHz) NMR spectroscopic data of compound 14 (in
MeOD, δ in ppm, J in Hz).
Position
1
2
1’
2’, 6’
3’, 5’
4’
1”
2”

Multiplicity
C≡N
CH2
C
CH
CH
C
CH
CH

3”

CH

4”
5”
6”

CH
CH
CH3

1

H (δ)

3.81 (2H, s)
7.27 (2H, d, J=8.6 Hz)
7.07 (2H, d, J=9.6 Hz)

13

C (δ)
119.97
22.79
125.58
130.28
118.01
157.15
99.58
1.9 71.82

5.47 (1H, d, J=1.9 Hz)
4.07 (1H, dd, J=3.4,
Hz)
3.91 (1H, dd, J=9.5, 3.6 72.11
Hz)
3.51 (1H, t, J=9.5 Hz)
73.67
3.69 – 3.61 (1H, m)
70.59
1.24 (2H, d, J=6.3 Hz)
18.05
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4.3.2 Synthesis of compounds 1 and 14:
Compounds (1) and (14) were synthesized to confirm their structures and to obtain sufficient
material for performing biological tests. Our chemical synthesis scheme for compounds 1 and 14
starts with L-rhamnose monohydrate with acetylation step followed by regioselective
deprotection for the hidden anomeric position and subsequently lead to the trichloroacetimidate
derivative as rhamnosyl donor. The latter reacts with either 4-hydroxy benzylidene acetone or 4hydroxy benzene acetonitrile to produce omoringone (1) or niazirin (14), respectively, as
described in Scheme 4-1.

Scheme 4-1: Synthesis of compound 1 and 14:
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4.3.3 Cytotoxicity screening:
All the isolates were evaluated for their cytotoxicity against a panel of cancer and normal cell
lines (SK-MEL, KB, BT-549, SK-OV-3, Vero, LLC-PK1 and HepG2). No cytotoxicity effects
were observed on any tested cell lines at 100 µM (data not shown).

4.3.4 Inhibition of CYP isoforms by the MeOH extract of M. oleifera and its isolated
compounds:
The inhibitory effects of test samples on the catalytic activity of two major CYP isoforms
(CYP3A4 and CYP2D6) were measured. A decrease in the formation of the respective probe
metabolites was calculated, and the IC50 value (concentration responsible for a 50% decrease in
activity) was determined from concentration-response curves. The crude MeOH extract of M.
olefiera exhibited selective inhibition (IC50= 52.50 μg/mL) against CYP3A4 with no effect on
CYP2D6 at 100 μM. It was interesting to note that the activity of CYP3A4 was inhibited by
compounds 1-4, 9-11, and 13 in varying degrees range from 41.5 to 100 µM with no remarkable
effect observed on activity of CYP2D6 isozyme making them the potential major contributors
for the inhibitory activity of the extract against CYP3A4 as shown in Table 4-3.
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Table 4-3: Inhibition of CYP3A4 and CYP2D6 isozymes by Moringa oleifera extract and
isolated compounds

Test sample
MeOH extract
1
2
3
4
6
7
8
9
10
11
12
13
14
15
16

Omoringone
Rutin
Isoquercitrin
Astragalin
(S) Linalyl--D-glucoside
(S)-Linalyl--primeveroside
Euodionoside B
Lariciresinol 9-O--D-glucopyranoside
(+)-pinoresinol-4-O--D-glucopyranoside
Isolariciresinol-3a-O--D-glucopyranoside
2-hexenyl-β-D-glucopyranoside
Octadecadienoic acid
Niazirin
Benzyl--primeveroside
methyl 4-(-l-rhamnopyranosyloxy)benzylcarbamate
Ketoconazole*
Quinidine*

CYP3A4 CYP2D6
IC50 µg/mL
52.50
IC50 µM
54.00
>100
82.50
70.00
>100
84.00
90
>100
>100
72.50
41.50
100.00
51.50
>100
>100
>100
>100
0.04
0.05

(-) indicates the lack of inhibition, (*) indicates the positive control for respective
CYP450 isozyme. The data are represented as mean ± SD of three independent
experiments
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4.4

Discussion:

Owing to the ethnobotanical significance of this plant species, the prime research aims to assess
the phytochemical profile, cytotoxicity effect and drug interaction potential for the extract and
isolated unique secondary metabolites from M. oleifera. All isolated secondary metabolites were
obtained from the methanol soluble portion of M. oleifera leaves by diverse column
chromatographic techniques (silica gel, RP-18 silica gel, and Sephadex LH-20) as well as
preparative TLC over silica gel. The isolated compounds represent a variety of chemical classes
such as flavonoid, terpenoid, lignan and phenyl alkenoid glycosides. To the best of our
knowledge, compound 1 found to be a new metabolite. Also, this is the first report for
compounds 5-10 and 13 from this species. In addition, compounds 14 and 16 are analytical
markers for M. oleifera species, and they could be employed for the chemical fingerprinting
profile of M. olefiera and quality control for herbal supplements claimed to contain this plant
species.
The molecular formula of compound 1 was determined as C16H20O6 which was compatible with
the molecular ion peak at m/z 308.1250 (calcd. for C16H20O6, 308.1260) and displayed seven
degrees of unsaturation. Investigation of HMQC, COSY, and HMBC spectra allowed assigning
the 1H NMR and 13C NMR spectroscopic data. Decoupled 13C NMR spectrum exhibited sixteen
resonances which were distinguished as two methyl, eleven methine, and three non-protonated
carbons using DEPTQ135 experiment. Among them, the compound includes a carbonyl moiety
(201.33 ppm) and one deoxy hexose sugar moiety which was identified as -Lrhamnopyranoside based on coupling constants 3J H-1”, H-2” = 1.7 Hz. Besides, 1H NMR displayed
AB spin system characterized with roofing effect indicating aromatic ring with symmetry as 1, 4
disubstituted benzene. Two additional ethylenic carbons were observed (126.27 and 145.36 ppm)
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which reveals the existence of a double bond. Its geometry was assigned as (E) configuration
based on the high J-value between the vicinal protons equals 16.3 Hz. A singlet (3H) at 2.38 ppm
was observed which was indicative to the presence of acetyl group. The HMBC cross-peak
correlations of the anomeric proton for Rhap (H 5.52) with C-4’ (C 159.83) indicated that
glycone residue was located at C-4’ (Figure 4-59). All this data was evident to elucidate the
structure as (E)-4-[4-[(-L-rhamnopyranosyl)oxy]phenyl]but-3-en-2-one.

Figure 4-59: The key HMBC (arrows) and 1H-1H COSY (bold lines) correlations of compounds
1 and 14
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The putative proposed biosynthesis for compound 1 is illustrated in Scheme 4-2. It is
biosynthesized from the shikimic acid pathway via conversion the phenylalanine moiety to
cinnamic acid by phenylalanine ammonia lyase followed by aromatic hydroxylation via CYP450
to provide p-coumaric acid. The latter was catalyzed by P-coumarate-CoA ligase to yield pcoumaroyl-CoA. Benzalacetone synthase (BAS) forms the polyketide intermediate phydroxybenzalacetone through the decarboxylative (Claisen-type) condensation of p-coumaroylCoA with malonyl-CoA, followed by hydrolysis and decarboxylation.(Koeduka et al., 2011) In
the presence of rhamnosyl transferase as tailoring enzyme, the glycone moiety was incorporated
into the benzalacetone basic skeleton to provide compound 1.
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Scheme 4-2: Plausible biosynthetic pathway for compound 1:
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Because of the low isolation yields, compounds 1 and 14 were successfully synthesized to
confirm their structures and to obtain sufficient material for performing biological tests. This
work constitutes the first synthesis for the compounds 1 and 14. Comparison of 1H NMR spectra
for natural and synthesized omoringone (1) and niazirin (14) are illustrated in Figure 4-60 and
Figure 4-62, respectively. Comparison of
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C NMR spectra for natural and synthesized

omoringone (1) and niazirin (14) are shown in Figure 4-61 and Figure 4-63 respectively.

Figure 4-60: Comparison of 1H NMR spectra for natural and synthesized omoringone (1)
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Figure 4-61: Comparison of 13C NMR spectra for natural and synthesized omoringone (1)

Figure 4-62: Comparison of 1H NMR spectra for natural and synthesized Niazirin (14)
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Figure 4-63: Comparison of 13C NMR spectra for natural and synthesized Niazirin (14)

Multiple endogenous substrates and exogenous xenobiotics are predominantly metabolized and
biosynthesized by cytochrome P450. These heme-containing mono-oxygenases are exclusively
responsible for the conversion of the inactive prodrug to the pharmacologically active
metabolites in the human body. CYP inhibitors interact with CYP isozymes in the binding site
leading to interference with their substrates. Particularly, CYP inhibitors can intensify the
toxicity profile of other medicines being accumulated in the body. Although M. oleifera extracts
indicate a high degree of safety and there is no adverse effects reported in humans so far, some
studies highlighted that the chronic administration of M. oleifera extracts might distort the
histoarchitecture of both liver and kidneys which predispose to hepatic and kidney damage and
ultimately lead to hepatotoxicity and nephrotoxicity.(Ambi AA, 2011; Awodele et al., 2012;
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Oyagbemi et al., 2013; Paul CW, 2012) In the current study, we evaluated the extract and
isolated secondary metabolites from M. oleifera against the inhibitory activity of CYP450
isozymes (CYP3A4 and CYP2D6) which are responsible for 50% of drug metabolism. The new
compound, namely omoringone (1), in addition to the flavonols 2-4, and lignans 9-11 exhibited
the strongest inhibition against CYP3A4 ranged from 41.50 to 100 µM with no remarkable
inhibitory activity against CYP2D6 isoform. On the other hand, the monoterpenoids 6-7 and
norterpeoid 8 display no effect on both isozymes. Even though the flavonoids such as rutin and
hyperoside show different in vitro IC50 values, they are expected to exert similar inhibitory
effects in the animal model. This effect could be a consequence for the conversion of the
aforementioned flavonols to flavonol aglycone derivative, quercetin. The latter was extensively
evaluated and found to inhibit several CYP isozymes including CYP3A4, CYP2D6 and CYP2C9
according to prior in vivo studies.(Song et al., 2013; Valentova et al., 2014) Although the planar
structure for compound 5 was confirmed, the absolute configuration was not assigned because of
the very low yield, and it was excluded in the biologicals assays. Although compound 14 and 16
are considered as analytical markers for M. oleifera, they exhibited no inhibitory effects on both
CYP isozymes tested. This work aided in ascertaining components in M. oleifera with potential
HDI using in vitro human liver microsomes. Nonetheless, further studies should be conducted to
determine the bioavailability of the phytochemicals and extrapolate the findings to in vivo animal
model.
In conclusion, 16 secondary metabolites were isolated from M. olefiera leaves. Omoringone (1)
was found to be a new metabolite. Omoringone (1) and niazirin (14) were successively
synthesized to confirm their chemical structures and provide sufficient quantities for conducting
the additional bioassays. This work also constitutes the first synthesis for the two aforementioned
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compounds. No cytotoxicity effects were observed on any tested cell lines at 100 µM. The
extract exhibited an inhibitory effect on CYP3A4 isoform (IC50= 52.5 µg/mL). The inhibitory
activity against CYP3A4 was also observed with the compounds 1-4, 9-11, and 13 in an IC50
ranged from 41.5 to 100 µM with no remarkable effect on CYP2D6 isozyme.
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5

CHAPTER 5:

PROFILING AND QUANTIFICATION OF SELECTED PHYTOCHEMICALS
FROM THE MIRACLE TREE (MORINGA OLEIFERA) AND DIETARY
SUPPLEMENTS BY UHPLC-PDA-MS
Abstract:
Moringa oleifera Lam. is known as a drumstick tree that is widely cultivated in various
subtropical and tropical provinces. Beside antioxidant properties, it shows antihypertensive,
antimicrobial,

antidiabetic,

anticancer,

and

anti-inflammatory

activities

alongside

immunomodulatory, cardioprotectant, and hepatoprotectant effects. An ultra-high-performance
liquid chromatography method was developed for the determination of nine phytochemicals
from leaves of M. oleifera. The efficient separation was performed within 7 min with a
temperature of 45 °C by using a C-18 column as the stationary phase and water/acetonitrile with
0.05% formic acid as the mobile phase. The method validation for linearity, repeatability, limits
of detection, and limits of quantification was achieved. The limits of detection from 0.2 to 2
μg/mL was reported for the phenolic compounds (1-9) in this study. The photodiode array
detector at 220 and 255 nm wavelengths was recruited for quantification. The selected
phytochemicals were detected in the range from 0.42 to 2.57 mg/100 mg in thirteen dietary
supplements. This study considers the quantitative analysis for lignan derivatives biosynthesized
in M. oleifera for the first time. The characterization and confirmation of components from plant
samples and dietary supplements claimed to contain M. oleifera was achieved by LC-ESI-MS
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hyphenated technique. Extractive ion monitoring with the positive, [M+ H]+ and [M+ Na]+, and
negative, [M− H]− and [M – H+ HCO2H]− ion modes was involved for this purpose. The
optimized method was robust and suitable for chemical fingerprint analysis of M. oleifera and
simple, economical and rapid for quality control.
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5.1

Introduction:

Moringa oleifera Lam. is known as a drumstick tree that is widely cultivated in various
subtropical and tropical provinces. It belongs to the monogeneric genus Moringa beneath
Moringacea family. Among 13 species, M. oleifera has so far become the most commonly
used.(Saini et al., 2016) India and Africa are described as the origin for this species, but now it is
cultivated widely in all the seven continents. Since 2001, the number of international congresses
and scientific studies increased disseminating information about the incredible properties of this
species. Ayurvedic traditional medicine claims that M. oleifera can prevent 300 diseases, and it
has been called the miracle vegetable because all parts of Moringa such as pods, leaves, roots,
and seeds have been exploited to treat a variety of ailments. Beside antioxidant properties, it
shows antihypertensive, antimicrobial, antidiabetic, anticancer, and anti-inflammatory activities
alongside immunomodulatory, cardioprotectant, and hepatoprotectant effects.(Leone et al., 2015;
Stohs & Hartman, 2015)
Roughly, 110 compounds were reported from the Moringa genus including flavonoids,
glucosinolates, alkaloids, terpenoids, and lignans, and a multitude of therapeutic benefits for the
Moringa species is likely associated with this chemical diversity.(Abd Rani et al., 2018) The
abundant chemical classes reported are glucosinolates (thioglucoside conjugates) and flavonols
predominantly quercetin, kaempferol and isorhamnetin glycosides.(Amaglo et al., 2010)
Exploiting an array of well-characterized secondary metabolites as quality standards, isolated
from an authentic sample of M. olefiera, aids developing a chemical fingerprint profile which
serves as a guideline for accurate quantitative analysis of these phytochemicals in botanical
supplements claimed to contain M. olefiera. Prior studies focused mostly on the qualitative
analysis of M. oleifera compositions using structural interrogation by mass spectrometry. For
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instance, an extraction method to obtain a phenolic compounds-rich extract from M. olefiera
leaves were optimized, and mainly 30 flavonoids and phenolic acids among 59 components were
characterized for the first time.(Rodríguez-Pérez et al., 2015) Also, an untargeted metabolomic
study based on multivariate statistical analysis was performed between Chinese and Indian
ecotypes of M. olefiera leaves which identified 118 shared components among 122.(Lin et al.,
2019) Owing to the biogenetical capabilities, comparative study reported the glycosylation
complexity of M. oleifera compared with M. ovalifolia, which were glycosylated with only
rutinoside.(Charlene Makita et al., 2016) Other researchers identified 39 components from the
acetone extract of M. olefiera leaves with higher contents determined for acetylglucomoringin,
feruloylquinic acid, and caffeoylquinic acid using UPLC-Q-orbitrap-MS2.(Yan et al., 2019)
However, the followed quantitative analysis was mainly based on a semi-quantitative approach
which might provide inaccurate results. Limited quantification analysis was achieved such as the
determination of nitrile glycosides, niaziridin and niazirin contents in leaves and pods,(Shanker
et al., 2007) and the quantification of crypto-chlorogenic acid, isoquercitrin and astragalin in M.
oleifera leaves.(Vongsak et al., 2014) Comprehensive analysis of tissues including leaves, barks,
and roots of M. olefiera and M. stenpetala for profiling glucosinolates and phenolics was also
performed.(Bennett et al., 2003) However, the enormous suggestibility of UPLC compared with
HPLC will enable improving the resolution and reducing the total analysis time (40 min.).
Herein, overcoming the previous issues including misleading results provided by semiquantitative analysis along with delay analysis time affords an accurate, rapid and economic
analytical method. In our continued pursuit to explore the quality and safety of botanical
ingredients, this study aims to scrutinize the phenolic profile of M. oleifera via developing and
validating robust, suitable, and straightforward analytical fingerprinting approach which
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potentially aids in the identification and quantification of phytochemicals, and authentication of
the Moringa samples for quality assurance.
The current study was intended for the qualitative and quantitative analysis of nine selected
phenolic glycosides; two glucosinolate-derived hydrolysis products, four flavonoids, three
lignans of Moringa oleifera using ultra-high-performance liquid chromatography-photodiode
array-mass spectrometry (UHPLC‑PDA‑MS). The method is also applied to dietary supplements
claimed to contain M. oleifera. The nine standard compounds used as chemical markers were
methyl-4-(-L-rhamnopyranosyloxy) benzyl carbamate (1), niazirin (2), (+)-isolariciresinol-3aO--D-glucopyranoside (3), rutin (4), isoquercitrin (5), quercetin-3-O-(6-O-malonyl)--Dglucopyranoside (6), lariciresinol-9-O--D-glucopyranoside (7), (+)-pinoresinol-4-O--Dglucopyranoside (8), astragalin (9) as illustrated in Figure 5-1.
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Figure 5-1: Chemical structures of reference marker phytochemicals 1-9 from Moringa oleifera
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5.2

Materials and methods:

5.2.1 Chemicals and plant samples:
Secondary metabolites (1-5, and 7-9) were previously isolated and elucidated from the
authenticated plant material #18332 at the National Center for Natural Products Research
(NCNPR). The purity of the components was determined based on the 1H NMR spectrum and
HPLC chromatogram. Compound 6 was purchased from Sigma-Aldrich (St. Louis, MO, USA)
with 85% purity. The dried leaves of M. oleifera were obtained from Dr. Bello M. Oluwasesan,
Nigeria in August 2016. According to National Center for Natural Products Research (NCNPR)
guidelines for processing and packaging, the specimen (NCNPR # 18332) was prepared and
deposited by Dr. Vijayasankar Raman in the herbarium of NCNPR, school of pharmacy,
University of Mississippi. The morphological and chemical properties were compared with the
reference sample (NCNPR #11695) at the NCNPR as a process for the authentication. M.
oleifera supplements’ ingredients were identified by searching the websites. Thirteen brands of
dietary supplements listed as containing M. oleifera were purchased from online sources (Figure
S 2). All samples were assigned unique identifiers, and their representative samples were
deposited in the botanical repository of NCNPR in the University of Mississippi. The solvents
were purchased from Fisher Scientific (Fair Lawn, NJ) as analytical grade solvents.
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Table 5-1: NCNPR code, dosage form, serving size, and plant tissue of M. oleifera supplements

NCNPR code

Dosage form

Serving size

Additional notes

Plant tissue

20737

Powder

0.5- 4 Tea spoon

USDA organic

N/A

20738

Powder

N/A

N/A

leaf

20739

Capsule

3 capsules

1 capsule = 500 mg

leaf

20740

Powder

4 grams

USDA organic

leaf

20741

Powder

10 grams

USDA organic

leaf

20742

Powder

2 grams

N/A

leaf

20743

Powder

1-2 grams

USDA organic

leaf

20744

Powder

6 grams

USDA organic

leaf

20745

Powder

2 grams

USDA organic

leaf

20746

Capsule

500 mg

N/A

leaf

20747

Capsule

1 capsule

1 capsule = 5000 mg

extract (leaf)

20748

Capsule

2-4 capsules

USDA organic (1 capsule =500 mg)

leaf

20749

Capsule

400 mg

N/A

leaf

(N/A) indicates a lack of information.
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5.2.2 Preparation of standard solutions:
Stock solutions containing the standard compounds were prepared separately at a concentration
of 1 mg/mL in methanol. Seven different concentration levels were prepared to obtain the
calibration curves, and each level was injected in triplicate. The range of the calibration curves
was 1-100 μg/mL for the compounds 1-4, 7, and 9 while 1-500 μg/mL for compounds 5-6, and 8
based on the pilot study using a UHPLC‑PDA method (Table 5-2).
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Table 5-2: Calibration curves for compounds 1-9

Name
rutin
isoquercitrin
astragalin
quercetin malonyl
benzyl carbamate
niazirin
isolaricirecinol
laricirecinol
diepoxy lignan

Channel
255.0nm
255.0nm
255.0nm
255.0nm
220.0nm
220.0nm
220.0nm
220.0nm
220.0nm

R
0.999762
0.999290
0.999766
0.997536
0.999893
0.999826
0.999801
0.999482
0.999403
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R^2
0.999523
0.998581
0.999531
0.995079
0.999785
0.999653
0.999602
0.998965
0.998807

Equation
Y = 4.21e+003 X - 7.03e+002
Y = 6.12e+003 X + 7.46e+003
Y = 5.12e+003 X - 8.10e+002
Y = 4.48e+003 X + 1.27e+004
Y = 1.47e+003 X + 2.41e+002
Y = 3.95e+003 X + 7.56e+002
Y = 2.01e+003 X + 4.09e+002
Y = 1.66e+003 X - 5.06e+002
Y = 7.62e+002 X - 1.14e+003

5.2.3 Sample preparation:
Thirteen products were purchased either as a powder or capsule. For capsule, three representative
capsules were randomly taken, emptied and mixed to represent the final product and overcome
the sample non-homogeneity. Every product was ground to fine powder using Planetary Ball
Mill PM 400 (Retsch). Five hundred milligrams of dried powdered plant samples were weighed
then sonicated in 2.0 mL of 70% methanol for 30 min followed by centrifugation at 959 g for 15
min. A volumetric flask of 10 mL was used to accommodate the supernatant. The procedure was
repeated five times with 2.0 mL 70% methanol, and the respective supernatants were pooled.
The volumetric flask was adjusted to reach 10 mL final volume with 70% methanol then shaken
exhaustively. An adequate volume 2 mL was passed through a 0.45 μm polytetrafluoroethylene
membrane syringe filter into LC sample vial, and the remaining volume was collected in 10 mL
vial and stored in the refrigerator.
5.2.4 Validation procedure:
The newly developed UHPLC method was validated regarding linearity, precision, and accuracy
according to International Conference on Harmonization guidelines (ICH).("International
Conference on Harmonisation (ICH). ICH harmonised tripartite guideline – validation of
analytical procedures: text and methodology Q2 (R1). International Conference on
Harmonization, Geneva, Switzerland; 2005: 11–12.,") The LOD and LOQ were determined by
injecting a series of dilute solutions with known concentrations for each standard. Signal-tonoise ratio equal to three and ten was defined for LOD and LOQ, respectively. The method
accuracy was determined in duplicate using a concentration of 10 μg/mL for two samples. Three
consecutive days with triplicate each serves as a test for intra and inter-day variation of the assay.
5.2.5 Instrumentation and experimental conditions:
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Acquity UPLC system (Waters Corporation) was used to perform the analyses including the
quaternary solvent manager, sampler manager, column heater, and PDA detector connected to
Waters Empower 2 data station. An HSS T3, 1.8 μm, 2.1 x 100 mm also from Waters, was used.
The temperature for the column and sample were maintained at 45°C and 10°C, respectively.
The mobile phase, at a flow rate of 0.40 mL/min, included water (A) and acetonitrile (B) both
containing 0.05% formic acid were applied in the following gradient elution: 0-6 min, 85%
A:15% B to 72% A:18% B; 6-7 min, 72% A:18% B to 0% A:100% B. Washing procedure for 2
min with 100% B was applied after separation followed by a re-equilibration period for 4 min.
Strong and weak needle wash solutions (90/10 and 10/90; acetonitrile/water) were performed,
respectively. The total run time for analysis was 7 min. The injection volume was 2 μL, and the
compounds were detected at 220 nm for glucosinolate hydrolysates 1-2 and lignans 3, and 7-8,
and 255 nm wavelengths for flavonoids 4-6, and 9. Spiking the samples with standard
compounds then comparing the UV spectra and retention times were necessary for peaks
assignment. The mass spectrometric analysis was conducted with a single quadrupole detector
(SQD) equipped with an ESI source using the following parameters: capillary voltage 3.0 kV,
cone voltage 30 V, source temp 150 C, desolvation temp 350 C, and desolvation gas 650 L/h in
positive and negative mode. The positive and negative ion modes in the range of m/z 100–900
were applied for samples analysis.
5.3

Results:

5.3.1 Isolation and structure elucidation:
Phytochemical investigation of the MeOH extract of M. olefiera leaves resulted in the isolation
and characterization of two glucosinolate hydrolysates; methyl-4-(-L-rhamnopyranosyloxy)
benzyl carbamate (1), and niazirin (2), three lignan derivatives; (+)-isolariciresinol-3a-O--D-
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glucopyranoside (3), lariciresinol-9-O--D-glucopyranoside (7), and (+)-pinoresinol-4-O--Dglucopyranoside (8), and three flavonoid derivatives; rutin (4), isoquercitrin (5), and astragalin
(9). Structure elucidation for the isolated standards was mainly achieved by spectroscopic data
analysis including 1D and 2D NMR (1H,

13

C, DEPTQ135, COSY, HSQC, and HMBC), and

confirmed by HR-ESI-MS data. Based on NMR data and the chromatograms, the purity of
phytoconstituents 2-5, and 7-9 was approximately 90-95% while the purity for compounds 1 was
85%. Quercetin-3-O-(6-O-malonyl)--D-glucopyranoside (6) was purchased from (SigmaAldrich) with purity 85%.
5.3.2 Sample Preparation:
The plant samples were composed of complex mixtures of components, and three extraction
techniques were employed. The authenticated plant sample (#18332) was extracted separately
with methanol, 80% methanol, and 70% methanol in water exhaustively to quest the optimal
extraction solvent. The abundance values for compounds 1-9 in the sample extracted with 70%
methanol was found to be higher than the samples extracted with pure methanol or 80%
methanol in water.
5.3.3 Method development and optimization:
Optimized chromatographic conditions were achieved after several trials with acetonitrile,
methanol, and water in different proportions for the mobile phase. A mobile phase containing
water and acetonitrile, both containing formic acid with a constant flow rate at 0.40 mL/min on
an HSS T3, 1.8 μm, 2.1 x 100 mm using gradient elution at a fixed column temperature of 45°C
were deemed the optimal separation condition for the determination of compounds 1-9 in various
samples. The different columns tried were Acquity UPLC BEH Shield RP18, 1.8 um, 2.1 x 100
mm, and Cortecs UPLC C18, 1.6 um, 2.1 x 100 mm. Each provided a different combination of
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silanol activity, hydrophobicity, hydrolytic stability, and chemical interaction with the analytes.
Among these, the HSS T3, 1.8 μm, 2.1 x 100 mm resolved peaks 1-9 adequately. Other columns
could not resolve the lignan derivatives 7 and 8 satisfactorily under the same conditions.
5.3.4 Method Validation:
Quantitative determination of nine compounds in various samples was achieved using the
UHPLC‑PDA method, and results were expressed as mg/100 mg on a dry weight basis. The
developed method was validated regarding sensitivity (limit of detection [LOD] and limit of
quantification [LOQ]), linearity, intra-day and inter-day precision for three consecutive days,
accuracy, specificity, stability, system suitability, and robustness. These validation parameters
enabled us to investigate the suitability of the method for routine analysis.
The seven-point calibration curve exhibited a linear correlation between concentration and peak
area. Calibration data indicated the linearity (r2 > 0.998) of the detector response for compounds
1-9 from 1 to 100 μg/mL, with additional concentration points (200-500 μg/mL) were considered
for compounds 5-6 and 8. The limits of detection were below 2 g/mL for compounds 1-9. All
samples and standard were injected in triplicate.
Intra- and inter-day variation for this study was determined for the authenticated M. oleifera
plant sample (#18332), and relative standard derivation (RSD) was lower than 6% except
compound 6. The analysis was conducted three times on three different days, and each run was
repeated in triplicate. The intra-day RSD for the replicates for compounds 1-9 were between 0.68
and 5.00% while RSD for the day-to-day replicates were between 2.9 and 5.7%. The intra-day
RSD for the replicates for compound 6 was 2.83, 4.28, and 0.85 for day 1, 2, and 3, respectively.
However, the inter-day RSD for the replicates was 9.2.
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The method accuracy for the related compounds was assigned by spiking samples (#18332) with
a known amount for a mixture of compounds 1-9. This sample was extracted exhaustively five
times, dried and spiked with known amount of the standard compounds then extracted and
analyzed again under similar conditions. The evaluation for the accuracy of the method was
evaluated in duplicate at a concentration of 100 μg/mL. The percentage recovery of these
samples ranged from 93.58 to 105.47%.
5.4

Discussion:

According to the World Health Organization (WHO), the described risks associated with
traditional medicines comprise undesirable side effects, exposure the individual to unreliable
information, and the consumption of inferior quality products. Bearing in mind the claims of
medical effectiveness, tremendous economic impact, and the possibility of herb-drug interaction,
there is a necessity to develop and validate analytical fingerprinting approach for identification
and quantification of the phenolic compounds as reference markers in Moringa samples.
Although several analytical methods have been applied for the qualitative and quantitative
analysis of moringa, the poor resolution, delay analysis time, and reduced sensitivity and
robustness hampered their suitability for routine applications. This highlights the necessity for
robust research aimed at standardizing Moringa herbal products and quality control.
M. olefiera is a prolific source for unique phytochemicals because of the ability for survival in
semiarid regions and adaptation for the environmental stressors. The predominant chemical
classes reported are glucosinolates (thioglucoside conjugates), and flavonols including quercetin,
kaempferol, and isorhamnetin glycosides. Previous studies described the complexity of the
flavonoid profile for M. olefiera which contains glucosides, rutinosides, malonylglucosides, and
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acetylglucosides. In addition, fatty acid profiling indicated that the leaves mainly contain
palmitic and linoleic acid.(Amaglo et al., 2010)
The UHPLC‑UV separation of 70% methanol extracts of M. oleifera at 220 nm shown in
Figure 5-2. Optimization strategies were pursued by modifying the temperature, flow rate,
mobile phase gradient and stationary phases. Although increased flow rate positively reduced the
analysis time, it simultaneously affected the resolution. All nine compounds were separated
within less than 7 min. The identification of the compounds in all samples was based on the
comparison of retention times and UV spectra with those of standards (Figure 5-3).
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Figure 5-2: UHPLC‑UV Chromatograms of a standards mixture (1-9), authenticated plant
sample (#18332) and selected dietary supplements (#20737, #20738, #20741, #20744, and
#20747) at 220 nm
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Figure 5-3: UV spectra for compounds 1-9
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The analysis was performed on an authenticated plant material (#18332) and 13 dietary
supplements. Of the 13 dietary supplement brands tested, all products contained phenolic
compounds with varied contents. The peaks of standard compounds in all samples were
identified by comparing the UV (Figure 5-3) and MS spectra (Figure 5-4) obtained with the
standards, which showed [M+ H]+ and [M+ Na]+ ions in the positive mode, and [M– H]− and
[M– H+ HCO2H]− ions in the negative mode (Table 5-3). The total content of phenolic
compounds analyzed (1–9) was found to be in the range from 0.42 to 2.57 mg/100 mg for the
herbal supplements (Figure 5-5).

Figure 5-4: The negative mode of mass spectra for compounds 1-9
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Table 5-3: Compound name, retention time (min), LOD, LOQ, λ max used for analysis, M.wt,
molecular formula, UV and MS spectra of compounds used for analysis of M. oleifera

Sampl
e No.*

1

2

Compound Name

tR
(min
)

LOD
(μg/mL
)

LOQ
(μg/mL
)

λ max
used
for
analysi
s

M.wt

Methyl 4-(-Lrhamnopyranosylox
y) benzylcarbamate

2.77
4

1

5

220

327.3
3

C15H21NO

Niazirin

2.92
6

0.5

279.2
9

C14H17NO

2

220

Molecular
formula

7

5

UV
(nm
)

m/z
[M +
H]+/
[M +
Na]+

220,
271

328.13

220,
271

3

(+)-Isolariciresinol3a-O--Dglucopyranoside

3.42
7

1

5

220

522.5
4

C26H34O11

202,
227,
283

4

Rutin

3.79
2

0.5

2

255

610.5
2

C27H30O16

203,
255,
354

5

Isoquercitrin

4.30
7

0.2

1

255

464.3
7

C21H20O12

203,
255,
353

6

Quercetin 3-O-(6-Omalonyl)-Dglucopyranoside

5.29
5

0.5

2

255

550.4
2

C24H22O15

204,
255,
354

7

Lariciresinol 9-O-D-glucopyranoside

5.66
6

1

5

220

522.5
4

C26H34O11

227,
280,
340

8

(+)-pinoresinol-4-O-Dglucopyranoside

5.95
5

2

10

220

520.5
3

C26H32O11

201,
227,
278

9

Astragalin

6.27
7

0.5

2

255

448.3
8

C21H20O11

265,
347

*The number for the reference compounds are corresponding to the elution order by the column
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302.18
[M +
Na]+
523.15
(frag.,
219.10
)
611.09
(frag.,
465.09
,
303.08
)
465.08
(frag.,
303.07
)
550.88
(frag.,
303.12
)
523.12
(frag.,
219.11
)
543.12
[M +
Na]+
(frag.,
341.13
,
235.09
)
449.08
(frag.,
287.08
)

m/z
[M – H]−/
[M – H+
HCO2H]−
372.09 [M –
H+
HCO2H]−
324.06 [M –
H+
HCO2H]−
521.30

609.18

463.16

549.12
(frag.,505.13
)

521.27

519.25
(frag.,357.04
)

447.18

3.0

2.5

2.0

% 1.5
1.0

0.5

0.0

20737
Lignans
0.55
Flavonoids 2.00
GDHP
0.02

20738 20739 20740 20741 20742 20743 20744 20745 20746 20747 20748 20749 18332
0.42
1.40
0.03

0.43
1.79
0.02

0.40
1.60
0.03

0.15
0.82
0.47

0.48
1.71
0.03

0.32
1.31
0.02

0.45
1.58
0.01

0.28
1.11
0.05

0.26
1.00
0.03

0.03
0.29
0.10

0.29
1.56
0.03

0.21
0.89
0.04

0.37
1.39
0.03

Figure 5-5: Quantitative analysis of phytochemicals (1-9) in authenticated plant sample
(#18332) and dietary supplements (#20737, #20738, #20739, #20740, #20741, #20742, #20743,
#20744, #20745, #20746, #20747, #20748, and #20749) were quantified at 220 for niazirin and
lignan derivatives while flavonoids were quantified at 255 nm. The results are arranged
according to the following; glucosinolate-derived hydrolysis products (GDHP) (methyl 4-(-Lrhamnopyranosyloxy) benzylcarbamate (1) ,niazirin (2)), lignans ((+)-isolariciresinol-3a-O--Dglucopyranoside (3), lariciresinol 9-O--D-glucopyranoside (7), (+)-pinoresinol-4-O--Dglucopyranoside (8)), and flavonoids (rutin (4), isoquercitrin (5), quercetin 3-O-(6-O-malonyl)-D-glucopyranoside (6), astragalin (9))
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The characterization and confirmation of nine compounds from plant samples and dietary
supplements claimed to contain M. oleifera was achieved by liquid chromatography-mass
spectrometry with electrospray ionization (LC-ESI-MS) coupled with selective ion monitoring.
All compounds of interest displayed the superior response in negative mode ionization. The
chromatogram shows no overlapping peaks at the retention time of interest. Also, the mass
spectrum exhibited fragmentation behavior which was diagnostic in the characterization of the
compounds (Table 5-3).
Particularly, the fragmentation pattern was distinctive in the characterization of compound 6
which was tentatively identified as quercetin 3-O-(6-O-malonyl)--D-glucopyranoside based on
the molecular ion peak and fragment ions. This compound was purchased, confirmed and
recruited as an additional reference marker compound. The method involved the use of both
positive and negative ion modes for compounds 1–9. The standard compounds in the positive ion
mode were observed at m/z 328.13 [M+ H]+, 302.18 [M + Na]+, 523.15 [M+ H]+, 611.09 [M+
H]+, 465.08 [M+ H]+, 550.88 [M+ H]+,523.12 [M+ H]+, 543.12 [M + Na]+, and 449.08 [M + H]+,
respectively. On the contrary, the standard compounds in the negative ion mode were detected at
m/z 372.09 [M– H+ HCO2H]−, 324.06 [ M– H+ HCO2H]−, 521.30 [M– H]−, 609.18 [M– H]−,
463.16 [M– H]−, 549.12 [M– H]−, 521.27 [M– H]−, 519.25 [M– H]−, and 447.18 [M– H]−,
respectively.
The absence of compound 1 from the fresh authentic plant material and all 13 herbal
supplements is justifiable. Previous studies reported the isolation of compound 1 from the
methanol extract of M. oleifera in conformance with our phytochemical study. Compound 1 was
previously reported as a potent hypoglycemic agent. However, compound 1 in the fresh plant
material and 13 herbal supplements was undetectable. We analyzed the old plant material
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(#18332) which has been phytochemically investigated to isolate and purify compound 1.
Interestingly, the compound was utterly absent according to our method. To understand the
hidden part of this puzzle, fresh plant material (500 mg) was sonicated for 2 h with six different
solvent systems (5 mL) each, separately. The extraction solvents used were methanol, 0.1 M HCl
methanol, ethanol, 0.1 HCl ethanol, acetonitrile, and water. All chemical profiles lack the peak
corresponding to compound 1 based on extractive ion monitoring. However, the absence of the
compound in the plant materials raised an issue regarding the source of the compound. It is
questionable whether this compound is a natural product or an artifact resulting from the
extraction and fractionation conditions. Knowing that the glucomoringin is the predominant
glucosinolate reported in M. olefiera, a plausible myrosinase dependent formation of compound
1 and 2 were illustrated in Figure 5-6. Generally, cutting M. oleifera converts the glucomoringin
precursor to free glucose and unstable intermediate followed by rearrangement to biologically
active nitrile, niazirin (2) and isothiocyanate derivative. This process is catalyzed by the
myrosinase enzyme released from an isolated compartment in the plant itself. Because of
stability issue, isothiocyanate derivative is vulnerable to further conversion in the presence of
nucleophilic such as a thiol or hydroxy groups resulting in thiocarbamate or carbamate
derivatives, respectively. Alongside the plausible myrosinase dependent formation, the absence
of compound 1 in multiple chemical profiles of the plant materials extracted with different
solvents indicated that compound 1 potentially to be an artifact as a consequence of the
fractionation conditions or present in traces below the limit of detection (1 µg/mL). A previous
study reported the inability to detect the thiocarbamates and carbamates in M. oleifera in
agreement of this result.(Bennett et al., 2003)
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Figure 5-6: Myrosinase-dependent formation of methyl 4-(-L-rhamnopyranosyloxy) benzyl
carbamate (1) and niazirin (2). Cutting and chewing M. oleifera convert the abundant
glucosinolate precursor (thioglucoside conjugate) to free glucose and unstable aglycone.
Ultimately, biologically active dietary nitrile and isothiocyanate (ITC) can be formed. This
process is catalyzed by myrosinase enzyme released from the plant itself or human gut
microbiota
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The content of niazirin (2) in the leaves of the authentic plant material (0.034 mg/100 mg) was in
conformance to what has been reported in the literature (0.038 mg/100mg) despite the variation
of the extraction procedure.(Shanker et al., 2007) However, the herbal supplements analyzed
exhibited different chemical profiles, and this reference marker was detected in varying amounts
between 0.010 – 0.468 mg/100 mg. Two samples contain higher content than other products as
0.468 and 0.970 respectively. This variation could be attributed to several factors such as
genetical background, environmental effects, cultivation methods, the tissue used, or the
myrosinase abundancy and the degree of activation.
Rutin (4) is known for its pharmacological activities and could be a contributor to the healthpromoting benefits of several medicinal plants. Because of the incapability for other plant
species to store rutin in large amount, prior study claims that Ethiopian Moringa (Moringa
stenpetala) has superior advantage to be one of the large-scale alternative sources for this widely
distributed flavonoid as its content was reported as 2.3 mg/100 mg.(Habtemariam & Varghese,
2015) However, rutin (4) was determined in the authentic sample of M. oleifera at 0.052 mg/100
mg in this study. Except for three samples (#20738, 20739 and 20744) which were determined as
0.480, 0.412, and 0.007 mg/100mg respectively, rutin (4) was detected between 0.018 to 0.076
mg/100 mg in other herbal samples. Among 12 ecotypes of M. olefiera, it was reported
previously that distributions of rutinoside-bearing flavonoids such as quercetin, kaempferol, and
isorhamnetin rutinosides were cultivar dependent, and only three samples contained them which
potentially interpret the discrepancy in the content of rutin (4) in the current study.(C. Makita et
al., 2017)
Although they have been structurally interrogated in preceding studies, this work considers the
quantitative analysis for lignan derivatives biosynthesized by M. oleifera for the first time.(Lin et
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al.,

2019;

Rodríguez-Pérez

et

al.,

2015)

Individually,

(+)-isolariciresinol-3a-O--D-

glucopyranoside (3), lariciresinol-9-O--D-glucopyranoside (7), (+)-pinoresinol-4-O--Dglucopyranoside (8) were analyzed qualitatively and quantitatively. Among them, compound (8)
was detected as the abundant lignan, and the content in the herbal supplements was varied
compared with its counterparts 3 and 7 which their percentages were around the authentic sample
range. According to the quantitative results, it was apparent that dietary supplements ((#20738
and 20739) which have higher content in rutin (4) associated with an increase in lariciresinol-9O--D-glucopyranoside (7). On the contrary, compounds 7 and 8 were qualitatively detected but
under the limit of quantification for the herbal supplement #20747. This product was labeled as
M. olefiera extract (10:1) specifying that the capsule contains the extract instead of the intact
leaves. The low abundance values might be associated primarily with the poor extraction method
by the manufacturer assuming that the applied approach was inappropriate to extract the
mentioned phytochemicals in measurable yields. Previous study highlighted the impact of the
extraction method on lignans which postulated that microwave-assisted extraction was superior
in

extraction

these

components

exhaustively

compared

to

pressurized

liquid

extraction.(Rodriguez-Perez et al., 2016) This observation shed light on the significance of good
manufacturing practices (GMP) for quality control in future studies.
Among the analyzed constituents, isoquercitrin (5) and quercetin 3-O-(6-O-malonyl)--Dglucopyranoside (6) predominates the leaves of M. olefiera which were in agreement with a
previous study reported that glucosinolates alongside the flavonoids, certainly the
aforementioned components, are the abundant phytochemicals detected in the leaves.(Bennett et
al., 2003) However, two products (#20741 and #20747) displayed contradicting patterns for
compound (6) with low abundance values detected as 0.271 and 0.025 mg/100 mg, respectively.
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Product #20741 has a content of nizairin (2) ten times higher than the authentic sample and other
herbal supplements. This observation speculates that product comprises other tissue parts instead
of entire leaves which contributed to the contrasting result. As mentioned earlier, herbal
supplement #20747 represented M. olefiera extract rather than the intact leaves, and the
extraction method might remarkably affect the chemical profile and the percentage of the
analyzed phytochemicals.
Knowing that the intra-day RSD for the replicates of compound 6 was 2.83, 4.28, and 0.85 for
day 1, 2, and 3, respectively while the inter-day RSD for the replicates was 9.2 enable us to
perceive the inherent degradable nature of compound 6. This could be a substantial characteristic
which affected the quantity of the compound in the authentic sample as shown in Table 5-4.
Although there was no apparent increase in isoquercitrin (5), it is likely that compound 6
converts rapidly to another component, acetylated isoquercitrin which might undergo further
hydrolysis slowly to provide isoquercitrin (5). Long-term stability studies in this regard are
warranted to illuminate the hydrolyzable character of compound (6) under altered conditions
including temperature, pH and time to highlight the impact of shelf life on quality of products.
Previous study stated that the malonyl glycosides of flavonoids in methanol extract were
thermolabile, and they were converted to its corresponding flavonoid glycosides when monitored
at 60°C for 24 h by HPLC-MS.(Coppin et al., 2013)
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Table 5-4: Percentage of isoquercitrin (5) and quercetin-3-O-(6-O-malonyl)--Dglucopyranoside (6) in authenticated plant material (#18332) in three consecutive days indicating
a decline in the quantity of quercetin 3-O-(6-O-malonyl)--D-glucopyranoside (6) without a
remarkable increase in isoquercitrin (5). The data suggests that quercetin 3-O-(6-O-malonyl)-D-glucopyranoside (6) hydrolyzes rapidly to quercetin 3-O-(6-O-acetyl)--D-glucopyranoside
which might undergo slow hydrolysis to provide isoquercitrin (5)

Compounds. (mg/ 100 mg sample)
Sample #

Compound Name
Day 1

Day 2

Day 3

5

Isoquercitrin

0.506 ± 0.004

0.508 ± 0.022

0.483 ± 0.013

6

Quercetin 3-O-(6-O-malonyl)--D-glucopyranoside

0.796 ± 0.007

0.749 ± 0.032

0.644 ± 0.018

The data are represented as mean ± SD (n=3). The samples were injected twice and averaged

193

In conclusion, the newly developed method is suitable for the quality control and chemical
fingerprint analysis for identification and quantification of compounds in plant samples and
dietary supplements claimed to contain M. oleifera. UHPLC‑PDA‑MS method for the
determination of phenolic compounds was found to be efficient in providing low retention times
and excellent resolution simultaneously. It was validated for all the parameters tested, and 13
dietary supplements were analyzed accordingly. All tested dietary supplements contained
phenolic compounds, and the quantities in these brands ranged from 0.42 to 2.57 mg/100 mg.
The difference in the phenolic contents between the authentic plant material and the
nutraceuticals stresses the significance of chemical fingerprint profiling and quantitative analysis
for quality assurance.
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SUPPLEMENTARY INFORMATION
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Figure S 1: Twenty-one brands of dietary supplements listed as containing A. linearis were
purchased from online sources. All samples were assigned unique identifiers, and their
representative samples were deposited in the botanical repository of NCNPR in the University of
Mississippi
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Figure S 2: Thirteen brands of dietary supplements listed as containing M. oleifera were
purchased from online sources. All samples were assigned unique identifiers, and their
representative samples were deposited in the botanical repository of NCNPR in the University of
Mississippi
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Current Occupation:
Research Assistant and Ph.D. candidate - Biomolecular Sciences Department - University
of Mississippi
Assistant professor - College of pharmacy - Pharmacognosy Department - King Saud
University
E-mail Address:
O.fantoukh@gmail.com / oifantou@go.olemiss.edu

EDUCATION
 Ph.D. in Pharmaceutical Sciences - University of Mississippi Aug 2014 - now
(anticipated May 2019)
 Master of health and hospital administration - King Saud University (KSU) - studied
for a year and a half 2013 (suspended)
 Bachelor of pharmacy - (KSU) - Pharmacy Sciences 2011
RESEARCH INTERESTS
 Extraction, fractionation, isolation, and purification of bioactive secondary metabolites
with particular emphasis on anticancer agents and herb-drug interaction assessment
 De novo structure elucidation and characterization of natural product compounds
 Biosynthetic pathways of chemical classes derived from natural products
 Synthesis of natural product derivatives based on molecular docking studies
 Developing validated analytical methods using the isolated markers and hyphenated
UPLC-MS technique for chemical fingerprinting and standardization of nutraceuticals
and herbal supplements
PEER-REVIEWED PUBLICATIONS
1. Fantoukh, O., Dale, O. R., Parveen, A., Hawwal, M. F., Ali, Z., Manda, V.,
Chittiboyina, A. G., Viljoen, A. M., Khan, I. A., & Khan, S. I. (2019). Safety Assessment
of Phytochemicals Derived from the Globalized South African Rooibos Tea (Aspalathus
linearis) Through Interaction with CYP, PXR, and P-gp. Journal of Agricultural and
Food Chemistry.
2. Osman, A., Ali, Z., Fantoukh, O., Raman, V., Kamdem, R., & Khan, I. (2018).
Glycosides of ursane-type triterpenoid, benzophenone, and iridoid from Vangueria
agrestis (Fadogia agrestis) and their anti-infective activities. Natural product research.
3. Avula, B., Bae, J., Raman, V., Fantoukh, O., Wang, Y., Osman, A., Wang, M., Ali, Z.,
& Khan, I. (2018). Quantification of Phenolic Compounds from Fadogia agrestis and
Dietary Supplements using UHPLC-PDA-MS. Planta Medica.
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PUBLISHED CONFERENCE ABSTRACTS
1. Fantoukh, O., Ali, Z., Parveen, A., Viljoen, A., & Khan, I. (2016). Flavonoid C- And Oglycosides from Aspalathus linearis. Planta Medica, 82(05).
2. Parveen, A., Ali, Z., Fantoukh, O., & Khan, I. (2016). Phytochemical constituents of
Tinospora Sinensis. Planta Medica, 82(05)
MANUSCRIPTS SUBMITTED/IN PROGRESS
1. Fantoukh, O., et al. Chemical fingerprint profile and comprehensive quantitative
analysis of phenolic compounds from South African rooibos tea (Aspalathus linearis) and
dietary supplements using UHPLC-PDA-MS (submitted to Journal of Pharmaceutical
and Biomedical Analysis)
2. Parveen, A., Huang, Y., Fantoukh, O., et al. Rearranged clerodane diterpenoid from
Tinospora crispa. (submitted to Natural Product Research)
3. Fantoukh, O., et al. Isolation, synthesis, and drug interaction potential of secondary
metabolites derived from the miracle tree (Moringa oleifera) leaves against CYP3A4 and
CYP2D6 isozymes (submitted to Phytomedicine)
4. Fantoukh, O., et al. Profiling and quantitative analysis of selected phytochemicals from
the miracle tree (Moringa oleifera) and dietary supplements by UHPLC-PDA-MS (in
progress)
PRESENTATIONS (ORAL/ POSTER)
1. Fantoukh, O., Wang, Y., Parveen, A., Ali, Z., Hawwal, M., Khan, S., Chittiboyina, A.,
Viljoen, A., & Khan, A. Drug interaction potential (CYP-PXR-P-gp) and comprehensive
quantitative analysis for phytochemicals derived from the globalized South African
rooibos tea (Aspalathus linearis) and dietary supplements using UHPLC-PDA-MS. 19th
International Conference on the Sciences of Botanicals. Oxford, MS, USA. Apr 09, 2019
2. Hawwal, M., Fantoukh, O., Ali, Z., Khan, A. Phytochemical Investigation of Mimosa
pigra. 19th International Conference on the Sciences of Botanicals. Oxford, MS, USA.
Apr 09, 2019
3. Osman, A., Fantoukh, O., Ibrahim, M., Zaki, A., Raman, V., Ali, Z., Khan, S., and
Khan, A. Monoterpene glycosides from the aerial parts of Vangueria agrestis. 19th
International Conference on the Sciences of Botanicals. Oxford, MS, USA. Apr 09, 2019
4. Parveen, A., Fantoukh, O., Wang, Y., Mir, T., Ashfaq, M., Ali, Z., Raman, V., Khan, I.
Phytochemical Investigation, Safety and Quality Assessment of Two Tinospora Species.
19th International Conference on the Sciences of Botanicals. Oxford, MS, USA. Apr 09,
2019
5. Majrashi, T., Khan, S., Ashpole, N., Zulfiqar, F., Fantoukh, O., Chittiboyina, A., Ali, Z.,
and Khan, I. Chemical and Biological Evaluations of Asimina triloba. 19th International
Conference on the Sciences of Botanicals. Oxford, MS, USA. Apr 09, 2019
6. Fantoukh, O., Dale, O., Ali, Z., Parveen, A., Manda, V., Khan, S., Chittiboyina, A.,
Viljoen, A., & Khan, A. Safety assessment on drug interaction potential (CYP-PXR-Pgp) of phytochemicals derived from popular South African rooibos tea (Aspalathus
linearis). 22nd School of Pharmacy Annual Poster Session. Oxford, MS, USA. Oct 12,
2018
7. Haron, M., Fantoukh, O., Chittiboyina, A., Khan, I., and Khan, S. PXR-mediated
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induction of CYP enzymes by Chinese club moss Huperzia serrata. 22nd School of
Pharmacy Annual Poster Session. Oxford, MS, USA. Oct 12, 2018
8. Hawwal, M., Fantoukh, O., Ali, Z., & Khan, I. Phytochemical investigation of Mimosa
pigra. 22nd School of Pharmacy Annual Poster Session. Oxford, MS, USA. Oct 12, 2018
9. Parveen, A., Maqbool, T., Fantoukh, O., Ali, Z., Wang, Y., Raman, V., Ashfaq, MK., &
Khan. I. Isolation of secondary metabolites of Tinospora crispa and Tinospora sinensis
and assessment of hepatotoxic potential of major furanoditerpenoids in murine model.
22nd School of Pharmacy Annual Poster Session. Oxford, MS, USA. Oct 12, 2018
10. Avula, B., Bae, J., Raman, V., Wang, Y., Fantoukh, O., Osman, A., Wang, M., Ali, Z.,
& Khan, I. Quantification of iridoid and phenolic compounds from roots and aerial parts
of Fadogia agrestis and dietary supplements. Annual Meeting for American Society of
Pharmacognosy. Lexington, KY, USA. July 24, 2018
11. Fantoukh, O., Dale, O., Ali, Z., Parveen, A., Manda, V., Khan, S., Chittiboyina, A.,
Viljoen, A., & Khan, A. Phytochemicals derived from the popular South African rooibos
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12. Fantoukh, O., Albadry, M., Hawwal, M., Parveen, A., Majrashi, T., Ali, Z.,
Chittiboyina, A., & Khan, I. Isolation, characterization and synthesis of secondary
metabolites derived from the miracle tree (Moringa oleifera) leaves. Annual Meeting for
American Society of Pharmacognosy. Lexington, KY, USA. July 23, 2018
13. Haron, M., Fantoukh, O., Chittiboyina, A., Khan, I., and Khan, S. PXR-mediated
induction of CYP enzymes by Chinese club moss Huperzia serrata. 18th International
Conference on the Sciences of Botanicals. Oxford, MS, USA. April 11, 2018
14. Hawwal, M., Fantoukh, O., Ali, Z., & Khan, I. Phytochemical investigation of Mimosa
pigra. 18th International Conference on the Sciences of Botanicals. Oxford, MS, USA.
April 11, 2018
15. Osman, A., Ali, Z., Fantoukh, O., & Khan, I. Chemical constituents from the aerial parts
of Vangueria agrestis. 18th International Conference on the Sciences of Botanicals.
Oxford, MS, USA. April 11, 2018
16. Parveen, A., Ali, Z., Fantoukh, O., & Khan, I. Exploring the chemical diversity of two
species of Tinospora. 8th Annual Graduate Student Council Research Symposium. May
10, 2018
17. Parveen, A., Ali, Z., Fantoukh, O., Shokoohinia, Y., Wang, Y., Raman, V., & Ikhlas A.
Khan. Secondary metabolites of Tinospora sinensis and Tinospora crispa. 18th
International Conference on the Sciences of Botanicals. Oxford, MS, USA. April 11,
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18. Parveen, A., Ali, Z., Fantoukh, O., & Khan, I. Exploring the chemical diversity of two
species of Tinospora. 21st School of Pharmacy Annual Poster Session. Oxford, MS, USA.
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20. Hawwal, M., Fantoukh, O., Ali, Z., & Khan, I. Phytochemical investigation of Mimosa
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Portland, OR, USA
22. Fantoukh,O., Ali, Z., Parveen, A., & Khan, I. Phytochemical constituents from Moringa
oleifera. 17th International Conference on the Sciences of Botanicals. Oxford, MS, USA.
April 5, 2017
23. Parveen, A., Ali, Z., Fantoukh, O., & Khan, I. Phytochemical constituents of Tinospora
Sinensis. 20th School of Pharmacy Annual Poster Session. Oxford, MS, USA. Oct 7, 2016
24. Fantoukh, O., Ali, Z., Parveen, A., Viljoen, A., & Khan, I. Flavonoid C- And Oglycosides from Aspalathus linearis. 20th School of Pharmacy Annual Poster Session.
Oxford, MS, USA. Oct 7, 2016
25. Fantoukh, O., Ali, Z., Parveen, A., Viljoen, A., & Khan, I. Flavonoid C- And Oglycosides from Aspalathus linearis. 16th International Conference on the Sciences of
Botanicals. Oxford, MS, USA. April 5, 2016
26. Parveen, A., Ali, Z., Fantoukh, O., & Khan, I. Phytochemical constituents of Tinospora
Sinensis. 16th International Conference on the Sciences of Botanicals. Oxford, MS, USA.
April 5, 2016
27. Fantoukh, O., Alasmari, F., Asiri, B, Al-amri, Y., Fakeha, A., Algunaim, A. Evaluation
of directly compressed tablets prepared from different grades of avicel. Riyadh, SA. Jan
10, 2011
EXPERIENCES
 Teaching Assistant:
Pharmacognosy department - college of pharmacy - King Saud University (from 18
December until now).
 Pharmacist:
Saudi Food and Drug Authority (SFDA) from16 July 2011 until 9 December 2012
 Pharmacist:
King Fahad Medical City (KFMC) from 12 April until 12 July 2011
 Trainee:
King Fahad Medical City(KFMC) for 250 hours from 1 August to 14 September 2009
including:
DPIC (Drug and poison information center), in-patient, outpatient, I.V room,
prescription, dispensing and making presentation
 Trainee:
Pfizer Company from 17 July to 17 August 2010
 Trainee:
Health House Pharmacies Group for 126 hours (almost 20days)
 Trainee:
International Riyadh Exhibition Centre as exhibitor from12 April – 15 April
PROFESSIONAL MEMBERSHIP AND HONORS
 Reviewer (Natural Product Research Journal)
 Graduate Student Grant, Saudi Arabia Cultural Misssion (SACM)
 Treasurer (Saudi Student Association at University of Mississippi)
 Treasurer (Saudi Club in oxford, MS supervised by Saudi Cultural Mission)
 King Saud University Scholarship
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Ph.D. in Pharmaceutical Sciences, University of Mississippi (Overall GPA: 3.97)
Rho Chi Society
Golden Key International Honor Society
Gamma Beta Phi Honor Society
The American Society of Pharmacognosy
American Chemical Society
Saudi Pharmaceutical Society

CONFERENCES AND TRAINING COURSES
 19th International Conference on The Sciences of Botanicals
Place: Oxford, MS, USA
Date: 8 - 11 Apr 2019
 LC/MS Sci-Dev Day Seminar Series: Developing And Accelerating Your Mass Spec
Expertise By Agilent
Place: Memphis, TN, USA
Date: 6th Dec 2018
 Writing in the Sciences by Stanford University
Place: Coursera online
Date: 24 Oct-19 Nov 2018
 Annual Meeting for American Society of Pharmacognosy
Place: Lexington, KY, USA
Date: 21-25 July 2018
 18th International Conference on The Sciences of Botanicals
Place: Oxford, MS, USA
Date: 9-12 Apr 2018
 17th International Conference on The Sciences of Botanicals
Place: Oxford, MS, USA
Date: 3-6 Apr 2017
 Natural Products Training Course Provided By Water
Place: Oxford, MS, USA
Date: 13-17 Mar, 2017
 16th International Conference on the Science of Botanicals (ICSB) & 5th Interim
American Society of Pharmacognosy (ASP)
Place: Oxford, MS, USA
Date: 11-14 Apr 2016
 42nd Annual MALTO Medicinal Chemistry–Pharmacognosy Meeting
Place: Oxford, MS, USA
Date: 17-19 May, 2015
 15th International Conference on The Sciences of Botanicals
Place: Oxford, MS, USA
Date: 8-11 Apr, 2015
 Introduction of European Regulatory Affairs
Place: Cambridge, UK
Date: Aug, 2012
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Medication Safety: A Mission for All Symposium
Place: Riyadh, SA
Date: 13-14 Apr, 2010
8th International Saudi Pharmaceutical Conference.
Place: Riyadh, SA
Date: 25-28 Apr, 2010
1st International Cardiovascular Pharmacotherapy Conference and Exhibition.
Place: Riyadh, SA
Date: 12-13 Jan, 2010

CERTIFICATES
 Certificate of an advanced level at Tutorium in Intensive English at University of Illinois
at Chicago during the summer session 2013
 Certificate of a high intermediate level at Tutorium in Intensive English at University of
Illinois at Chicago during the summer session 2013
 An excellence’s award at pharmacy school for the last year
 Certificate of completion for the fourth level in English Language offered by Al-Faisal
International Academy, in Affiliation with Imam Mohammed Ibn Saud University. 27 – 7
– 2005
 Certificate of completion for the third level in English Language offered by Al-Faisal
International Academy, in Affiliation with Imam Mohammed Ibn Saud University. 28 – 7
– 2004
 Receiving trophy of the 6th on Physics Competition and was represented the region
 Trophy of academic excellence at the level of the Riyadh region 2004 – 2005
 Trophy of academic excellence at the level of the Riyadh region 2003 – 2004
SKILLS
Decision maker – deep thinker – good listener and talker in a diplomatic manner – cooperative
and collaborative – time management – self-control – creative – honest – hard worker – active
and proactive – good writing, reading and listening in English/Arabic languages – critical
thinking and ability to accept constructive criticism – ability to persuade
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